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IMPACT OF STATIN THERAPY ON OUTCOMES IN ANEURYSMAL 
SUBARACHNOID HEMORRHAGE PATIENTS  
 
By Abdulkhaliq Jassem Alsalman, M.S. 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master at 
Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director:  Dr. Gretchen Brophy 
Professor of Pharmacy and Neurosurgery 
 
 
 
There is conflicting data on the effects of statins on cerebral vasospasm and clinical 
outcomes in aneurysmal subarachnoid hemorrhage (aSAH) patients. In this retrospective 
cohort study, patients were divided into those who received pravastatin (PRAV group) 
40mg/d and those who did not (NP group). Data were analyzed using multivariate logistic 
xv 
 
 
 
regression. Eighty-one patients met inclusion criteria.  There was a statistically significant 
decreased in the incidence of vasospasm in the PRAV group; however, this association did 
not retain significance after adjusting for WFNS, race, elevated WBC, and clipping (59% 
PRAV vs. 88% NP, p=0.08). There was no statistically significant difference in proportion 
of severe radiological vasospasm or mortality between groups. However, there was a trend 
towards a decreased mean length of stay (P=0.06) and a significantly higher proportion of 
survivors discharged to home in the PRAV group (P<0.0001). In conclusion, there was a 
trend towards a decrease in the incidence of vasospasm in the aSAH receiving pravastatin, 
but this trend did not achieve statistical significance after adjusting for potential 
confounders.   Pravastatin was associated with other favorable clinical outcomes.   
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CHAPTER 1 INTRODUCTION 
 
Background and Significance 
Subarachnoid hemorrhage (SAH) accounts for around 3-5% of all strokes. (1, 2) 
Rupture of an intracranial aneurysm is the principal cause of nontraumatic SAH making 
up approximately 80% of all SAH cases. (3-5)  
  The incidence of SAH from a ruptured aneurysm is approximately 7.8/100,000 to 
21.4/100,000 (6, 7) with approximately 21,000 to 33,000 new cases of subarachnoid 
hemorrhage each year in the US. (2, 8) The initial hemorrhage after aneurysmal 
subarachnoid hemorrhage (aSAH) accounts for up to 50% of the death rate, (9) with an 
anticipated 30% of patients having some kind of disability after SAH.(3, 5)  
SAH is followed by histopathological damage to the cerebrovascular endothelium 
and depletion of endothelium-dependent relaxation factors, leading to vasospasm (10), 
which is one of the most dangerous complications following aneurysmal SAH. Cerebral 
vasospasm is defined as “the delayed narrowing of large capacitance arteries at the base 
of the brain after SAH, which is often associated with radiographic or cerebral blood flow 
(CBF) evidence of diminished perfusion in the distal territory of the affected artery”. (11)  
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Approximately 70% of SAH patients experience some degree of vasospasm, with 
20–30% developing ischemic symptoms.(12, 13) The major reason for morbidity in 
patients after the initial SAH is delayed cerebral ischemic (DCI) resulting from cerebral
vasospasm.(11, 12, 14) The fatality rate from vasospasm alone has been estimated to be 
between 15% and 50%. (11, 15) 
 
Factors Associated With Development of Vasospasm and DCI 
 
Medical literature identified many factors that predict the occurrence of cerebral 
vasospasm. Risk factors associated with the development of vasospasm and DCI are 
advanced age, (16) race (17), female patients, (2, 18-20) poor neurological status on 
admission, (21, 22) amount of exposure to subarachnoid blood, thick blood collections in 
basal cisterns and fissures, and intraventricular blood, (22-26) a longer duration of 
unconsciousness following the initial hemorrhage, (27) history of hypertension, (22, 28-
30) smoking, (31, 32) and a history of cocaine abuse. (33, 34)  
Although the exact pathogenesis of vasospasm is not fully understood, studies 
have suggested that cerebral vasospasm is most likely caused by nitric oxide (NO) 
depletion, inflammation activation, free radical damage, (35-38) enhanced platelet 
aggregation and leukocyte adhesion. (39) These effects can be provoked by blood 
products that continue rubbing the cerebral vessel wall following aSAH. (40) (Figure 1) 
Vasospasm usually occurs between days 4-7 days after aSAH. (12, 14) In patients with 
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aSAH a high temperature, headache and leukocytosis are frequently present and may 
indicate the beginning of vasospasm. (41, 42)  
 
Figure 1: Suggested mechanism of vasospasm after aSAH. Liu-Deryke, 
Pharmacotherapy 2006; 26:182-203 (43) 
 
 
Diagnosis of vasospasm 
Clinically, vasospasm can be identified through regular, comprehensive 
neurological examinations. Signs and symptoms can include changes in level of 
consciousness and mental status (measured by Glasgow Coma Scale [GCS]), severe 
headache, disorientation, confusion, dysphasia, aphasia, hemiplegia, hemiparesis, and any 
new motor deficits which are not due to seizure, hematoma, brain edema, hydrocephalus 
and structural or metabolic causes. (44, 45) The neurological deficits related to 
vasospasm may become temporary or permanent disabilities. (44) An increase in white 
blood cells (WBC) is significantly associated with increased risk of cerebral vasospasm 
after aSAH (46). Hypomagnesemia is common after aSAH and has been associated with 
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poor outcome and vasospasm. (47) Hypomagnesemia on admission occurs in 38% of 
individuals with aSAH. It is still controversial whether it predicts the development of 
DCI (48, 49)  
Cerebral vasospasm is determined radiologically by cerebral angiography and 
transcranial doppler ultrasonography (TCD) velocity. (50) Angiography (including CT 
angiography and magnetic resonance angiography) is the gold standard and the definitive 
study for the diagnosis of cerebral vasospasm with a sensitivity of 98% to 100% in the 
first 12 hours. (51-55) TCD imaging is a noninvasive technique often used to diagnose 
vasospasm. TCD studies are done at the bedside, generally on semi daily basis. TCD 
ultrasonography measures velocity of blood flow in cerebral arteries and can be useful in 
identifying and observing the degree of cerebral vasospasm after aSAH. (11) Contraction 
and tightening of the arterial lumen which takes place in cerebral vasospasm creates a rise 
of blood flow velocity which could be identified with TCDs (56, 57). Serial screening 
with TCDs currently is recommended for all patients with aSAH for the detection and 
monitoring of vasospasm. (58) Despite the high variability of specificity and sensitivity 
of TCD ultrasonography (50, 59-61), increasing blood flow velocities on serial TCD 
studies are usually reliable indicators of vasospasm (62, 63) and the reliability of 
recognizing the severity of cerebral vasospasm is high. (50, 64) Elevated blood-flow 
velocities (≥120 cm/sec) or increases of >50 cm/sec indicate cerebral vasospasm. (65) 
TCD findings are most reliable as predictors of vasospasm of the middle cerebral (MCA) 
and internal carotid (ICA) arteries. (63) The standard velocities for the middle cerebral 
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artery (MCA) are shown in Table 1. In order to distinguish vasospasm from hyperemia 
(which raises blood flow velocities in both the MCA and the ICA) and to avoid 
underestimating the number of patients having vasospasm, clinicians and researchers use 
the ratio of these velocities (known as Lindegaard ratio) also shown below in table 
(1).(66) The Lindegaard ratio is calculated bilaterally as the ratio of the MCA velocity to 
the ipsilateral extracranial ICA velocity with ratios below 3 indicating no vasospasm.(66) 
(Table 1) 
 
Table 1: Interpretation of transcranial doppler for vasospasm severity (66)  
 
Mean MCA velocity 
(cm/sec) 
MCA:ICA(Linegaard)ratio Interpretation 
<120 <3 Normal 
120-200 3-6 Mild vasospasm 
>200 >6 Severe vasospasm 
 
Grading Scales in aSAH 
The use of grading scales in aSAH patients is common. Several scales have been 
used in order to assess prognosis and clinical outcomes after SAH. These include Fisher 
Scale (FS), Hunt and Hess (HH) Scale, and the World Federation of Neurological 
Surgeons (WFNS) Scale. These scales have been validated in patients with aSAH.  
The Fisher CT grading scale is a helpful predictor of vasospasm.(23, 24) (Table 2) 
Fisher et al. linked the location and thickness of subarachnoid blood on CT with clinical 
outcome and possibility of emerging vasospasm. (67-70) Fisher classification is used to 
grade the thickness of the subarachnoid clot. (24) A thick layer of subarachnoid blood 
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and a poor initial clinical condition are known to elevate risk for poor clinical outcome, 
delayed cerebral ischemia, and hypodense lesions on CT scanning consistent with 
cerebral infarction.(11, 24, 30, 71) Previous studies have confirmed that Fisher grade was 
a statistically significant factor associated with vasospasm. (21-23, 31)  
The most commonly used scoring scales of severity of aSAH are the Hunt and 
Hess grading (Table 3), (72, 73) and the WFNS (Table 5). (74-77) For both of these 
scales, studies have indicated a direct correlation between the severity of the clinical 
grade of cerebral aneurysm and the incidence of vasospasm after aSAH. (22, 78) 
However, the interobserver agreement for the Hunt and Hess scale is poor (79). 
The WFNS scale is a commonly used scale and classified based on GCS and 
motor deficits. The Glasgow Coma Scale (GCS) is commonly used by clinician for 
consciousness assessment. (Table 4) The total GCS is the sum of the subcategory scores 
(eye, verbal, and motor response). A normal individual has a GCS = 15. A profoundly 
comatose patient has a GCS=3. Although focal motor deficits are known to be predictive 
of outcome after SAH, the GCS scale does not offer quantitative information related to 
focal deficits, but WFNS does. (74-77) Furthermore, the WFNS scale has been validated 
in patients with aSAH and commonly used to assess severity of brain injury upon 
admission. (74-77) 
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Table 2: Fisher CT Grading Scale (24) 
CT Fisher Grade                            Description of CT SAH 
1 No blood detected 
2 Diffuse, thin layer (<1mm). Subarachnoid hemorrhage less than 1 mm thick 
3 Localized clot or thick layer (>1mm). Subarachnoid hemorrhage more than 
1 mm thick 
4 Subarachnoid hemorrhage of any thickness with intra-ventricular 
hemorrhage (IVH) or parenchymal extension 
 
 
 
Table 3: Hunt and Hess scale (72)  
 
Grade Description 
1 Asymptomatic; or minimal headache and slight nuchal rigidity. Approximate 
survival rate 70%. 
2 Moderate to severe headache; nuchal rigidity; no neurologic deficit except cranial 
nerve palsy. 60%. 
3 Drowsy; minimal neurologic deficit. 50%. 
4 Stuporous; moderate to severe hemiparesis; possibly early decerebrate rigidity 
and vegetative disturbances. 20%. 
5 Deep coma; decerebrate rigidity; moribund. 10%. 
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Table 4: The Glasgow Coma Scale (80) for Mental Status Assessment  
Eye opening   
Spontaneous 4
In response to 
speech 
3
In response to pain 2
None 1
Best verbal 
response  
 
Oriented 
conversation 
5
Confused 
conversation 
4
Inappropriate words 3
Incomprehensible 
sounds 
2
None 1
Best motor 
response  
 
Obeys 6
Localizes 5
Withdraws 4
Abnormal flexion 3
Abnormal extension 2
None 1
 
 
Table 5: The World Federation of Neurosurgeons classification: (76)  
 
WFNS Grade Glasgow Coma Scale (GCS) Score        Motor Deficit  
1                 15 Absent 
2                 13-14 Absent 
3                 13-14 Present 
4                 7-12 Present or absent 
5                  3-6 Present or absent 
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Cerebral Vasospasm Classification  
Because of the different ways of identifying cerebral vasospasm (clinically or 
radiologically), cerebral vasospasm has been classified in different ways in the literature. 
One of the most commonly described classifications of vasospasm is as the following: 
(41, 45) 
- Absent (no clinical or radiological irregularity)  
- Asymptomatically present (radiological defect only) as the spasm can be evident 
on angiograms without clinical vasospasm manifestation. 
- Symptomatically present (clinical and radiological irregularity or clinical 
vasospasm only).  
Aneurysm Treatment 
Clipping the aneurysm or using endovascular coiling, within 72 hours of the 
initial hemorrhage reduces the risk of acute rebleeding, may decrease the length of 
hospital stay, (81, 82) and may be associated with lower rates of symptomatic vasospasm. 
(83-86) However, some researchers found early surgery may increase the incidence of 
secondary ischemia and a higher incidence of symptomatic vasospasm (87-89)  
 
Cerebral Vasospasm Treatment 
No definitive single treatment has been shown to manage cerebral vasospasm. 
Nevertheless; there are three major supports for the prevention and treatment of cerebral 
vasospasm after aSAH: calcium channel blockers, “triple H” therapy (hypertension, 
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hypervolemia, and hemodilution), and endovascular procedures. Nimodipine is the 
calcium channel blocker of choice and it is the only drug approved by the US Food and 
Drug Administration for use in prevention and treatment of vasospasm. It is safe, cost-
effective and most importantly reduces the risk of poor outcomes and secondary ischemia 
after aSAH. (90-97) Triple H therapy has become routine practice in many institutions, 
and is considered the standard of care for treatment of cerebral vasospasm after aSAH 
(83, 85, 98-100) The goal of Triple H therapy is to increase cerebral perfusion pressure, 
improve blood flow to the brain, and decrease the risk of ischemia.(85, 103-107) The 3 
elements of triple H therapy are hypertension, hypervolemia, and hemodilution. A 
hypertensive state is carried on through the use of vasopressors and intropic agents such 
as dopamine, phenylephrine, nonepinephrine, or dobutamine. Hypervolemia is achieved 
by using volume expansion, which then produces hemodilution. Isotonic crystalloid 
solutions and albumin have both been used to expand blood volume. (101)  These 
elements improve the symptoms of vasospasm more than treating the causes. (102) When 
medical therapy (nimodipine and triple H therapy) is used and does not reverse ischemic 
deficits, endovascular intervention with balloon angioplasty or direct arterial vasodilation 
is indicated, (108-113) but may not be feasible in each institution. Another treatment 
option that has been used is hypothermia. (114) 
A new therapeutic alternative for patients with vasospasm after aSAH is “statin” 
therapy. Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have a well 
recognized and powerful cholesterol-lowering activity. Previous experimental and 
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clinical studies have demonstrated that statins also have pleiotropic effects. Statins 
improve endothelial function and blood flow by promoting vasodilation by decreasing 
vascular inflammation, vascular smooth muscle cell proliferation, superoxide free radical 
formation, and platelet aggregation. It also up-regulates endothelial nitric oxide, which is 
a powerful vasodilator, free radical scavenger, and an inhibitor of platelet aggregation, 
vascular smooth muscle cell proliferation, and cell apoptosis. (115-119) Accordingly it 
would be expected that statins may also decrease the incidence of cerebral vasospasm 
after SAH and decreased its neurological complications. 
  Data from two small prospective clinical trials showed that treatment with 
pravastatin or simvastatin for 14 days reduced cerebral vasospasm and vasospasm-related 
ischemia. (120-122) Also, pravastatin 40mg therapy for 14 days has been shown to 
reduce mortality in aSAH. (135). In a third prospective study, Chou et al. concluded that 
simvastatin use for aSAH is safe and feasible but did not reach statistical significance. 
(123) In one retrospective study Parra et al. demonstrated that statins lessened the 
occurrence of delayed cerebral ischemia but outcome differences did not show a 
statistically significant reduction in mortality rate (124). In another recent retrospective 
study McGirt, et al. showed that statin treatment for 14 days had more than a 10-fold 
reduction in the incidence of developing cerebral vasospasm after aSAH. (125) In 
contrast to these studies, one retrospective study found that using statins may augment the 
incidence of cerebral vasospasm. (126) Also, Kramer et al. found that simvastatin was not 
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associated with a reduction in the incidence of vasospasm or improvement in outcomes. 
(127) 
 
Clinical Management Protocol for aSAH in Virginia Commonwealth University 
Health System (VCUHS) 
The treatments and procedures for aSAH patients have been consistent during the 
study period (Jan 2000-June 2008) except for the addition of pravastatin 40mg per day as 
standard therapy in 2005. The patient’s clinical condition at admission was usually 
graded according to the Hunt and Hess, Fisher or WFNS classification system at our 
institution.  Patients with angiographic evidence of an aneurysm underwent surgical 
clipping or endovascular coil embolization as early as possible. Nimodipine (60 mg every 
4 hours for 21 days) was started on admission of every patient with aSAH. Triple H 
therapy was started in patients under the suspicion of symptomatic vasospasm based on 
the clinical judgment of the treating neurosurgn. Patients were typically given 0.9% NaCl 
at a rate of 100-150 ml/hr, vasopressors drips (dopamine, phenylephrine, or 
norepinephrine), and Albumin 5% solution (250 ml every 4-6 hours intravenously) if 
vasospasm was diagnosed. Patients were monitored for vasospasm using TCD every 
other day at the bedside and hourly GCS evaluation. 
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Hypothesis  
Pravastatin 40mg therapy given within 72 hours of aSAH for 21 days will reduce 
the incidence of cerebral vasospasm; improve clinical outcomes and reduce mortality 
following aSAH.  
 
Rationale for Our Study 
Overall, it appears that statin therapy for up to 14 days may decrease cerebral 
vasospasm, decrease neurological and ischemic deficits, and reduce the morbidity and 
mortality of aSAH patients. However, published studies only evaluated statin therapy for 
duration of 14 days and a risk of rebound vasospasm have been suggested after 
discontinuation of statin therapy at day 14. No studies to date have evaluated the 
incidence of vasospasm following a 21-day course of statin therapy in aSAH patients. 
Also, there is conflicting data on the effects of statins on cerebral vasospasm and clinical 
outcome in aSAH patients. Studying an extended duration is reasonable based on the fact 
that cerebral vasospasm and DCI onset peak between days 4-7, and can occur up to 21 
days after aSAH. (12, 13, 40, 128-130) 
The dose of pravastatin 40mg was chosen based on a previous study that showed 
beneficial neuroprotective effects, decreased incidence of vasospasm and improved 
patient outcomes in a phase II trial. (120) Although simvastatin is more lipophilic, the 
previous studies did not show mortality benefit and, therefore, lipophilicity may not be a 
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factor when determining effectiveness for prevention and treatment of vasospasm. 
Additionally, this is the second study, which has focused exclusively on the effects of 
pravastatin therapy.  
 
Objectives  
 
The objective of this retrospective-cohort study was to determine if pravastatin 
therapy was associated with a decreased incidence of cerebral vasospasm and improved 
outcomes (mortality, length of stay, and discharge disposition) in aSAH patients. 
 
Specific Aims 
 
1- To determine whether pravastatin reduced the incidence of cerebral vasospasm 
after aSAH adjusting for potential confounders in multivariate logistic regression. 
2- To assess the incidence the symptomatic vasospasm and asymptomatic vasospasm 
between the two treatment groups (pravastatin and control) 
3- To test the difference in the incidence of vasospasm between the duration of 
pravastatin therapy variables (14 days or less and 15-21 days). 
4- To assess the incidence of severe radiological vasospasm after aSAH between the 
pravastatin-treated group and control group. 
5- To assess the effects of pravastatin on the frequency and duration of Triple H 
therapy after aSAH vasospasm. 
6- To identify and assess the effect of other covariates (confounders) on cerebral 
vasospasm after aSAH in our sample. 
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7- To assess the effects of pravastatin on mortality after aSAH. 
8- To assess the effects of pravastatin on the length of hospital stay and 
neurosciences intensive care unit (NSICU) length of stay. 
9- To assess the effects of pravastatin on survivor discharge disposition after aSAH. 
10- To assess the effects of cerebral vasospasm on mortality, length of hospital stay 
and survivors discharge disposition.
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CHAPTER 2 METHODS 
 
Study Design 
 This is a retrospective-cohort study of Neuroscience ICU patients with aSAH.   
This study was approved by the Virginia Commonwealth University Institutional Review 
Board in September 2008. 
 
Patients  
All patients (18 years of age or older) with aSAH who were admitted to the 
NSICU of VCUHS with the ICD-9 diagnosis code 430 (Subarachnoid Hemorrhage) 
between January 2000 and June 2008 were identified, and patient charts were 
retrospectively reviewed. Patient were divided into two groups, those who received 
pravastatin 40mg per day (PRAV group [2005-June 2008]) and those who did not (NP 
group [Jan 2000-Dec 2004]). Patients who presented within 48 hours of aneurysmal SAH 
were assessed for the incidence of cerebral vasospasm after receiving pravastatin 40mg 
per day or not receiving statin for 21 days. In the pravastatin group, patients were only 
included if they received pravastatin 40mg within 72 hours of symptom onset.  
Patients were excluded if they were diagnosed with nonaneurysmal SAH; were currently 
taking statins as part of their home medication regimen; or were discharged from the 
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NSICU or expire before post bleed day 3. We excluded patients participated in 
investigational drug or procedures (Endovascular intervention for vasospasm included 
either intra-arterial vasodilator administration or balloon angioplasty) intended to prevent 
or treat vasospasm 
 
Data Collection  
Patient demographics, and baseline characteristics, if available in the patients’ 
charts, were collected. Data included medical history, social and family history, initial 
aSAH grades on 48 hours admission or premorbid functional state (WFNS grade, Fisher 
scale, Glasgow Coma Scale, and Hunt and Hess scale), medications on admission, time to 
coil embolization of the aneurysm or to clip placements, and the occurrence of clinical 
vasospasm. Moreover, we collected the APR-DRG grade as a predictor of survival, 
hospital length of stay, and patient severity.  (131-134) Documentation of the 
hospitalization, clinical course, treatments, procedures, and complications were reviewed 
and evaluated for each patient. Clinical outcomes were determined from documented 
patient discharge disposition. 
Laboratory Data 
   The following laboratory data were collected from the patient’s charts: 
the white blood cell (WBC) count, magnesium levels, sodium serum level, and cardiac-
troponin-I.  Lab results were evaluated for 21 days or until discharge.  
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Elevated WBC: was defined as serum WBC > 11000 ng/dL on 2 consecutive 
measurements. 
Elevated Troponin-I: was defined as serum Troponin-I ≥ 2 mEq/L on 2 
consecutive measurements. 
Hypomagnesaemia: was defined as serum Mg++ < 1.3 mEq/L on 2 consecutive 
measurements. 
Hyponatremia: was defined as serum Na < 135 mEq/L on 2 consecutive 
 measurements. 
Anemia: ICD-9 code for anemia and two consecutive hemoglobin concentrations 
<10 g/dl. 
 
Radiological Data:  
The following radiological data were collected from the patient’s charts: presence 
and severity of cerebral vasospasm, presence of hydrocephalus, aneurysm 
location on cerebral angiography, and the TCD velocity values. 
During the study period; there were no changes in the management of aSAH at 
VCUHS (i.e. management parameters were standardized for all patients admitted 
with aSAH). All patients underwent clip ligation or coiling within 72 hours of 
aSAH. The clinical management of each patient included nimodipine for 21 days 
and moderate intravenous fluid supplementation.  
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Patient data were coded and de-identified. A key for the codes were stored 
separately until all data were collected. The keys were destroyed after data 
collection was completed.   
 
Definitions:  
Vasospasm was defined as either clinical or radiological. (Figure 2) 
Definition of Radiological Cerebral Vasospasm  
Patients will be considered to have radiological cerebral vasospasm if they had 
TCD ultrasonography flow velocities that are double of the baseline value or are ≥ 120 
cm/second; or have vasospasm as demonstrated on cerebral angiography. (Figure 2)  
 
Definition of Symptomatic (Clinical) Cerebral Vasospasm 
Patients were considered to have clinical cerebral vasospasm if they received 2 of 
the 3 aspects of triple-H therapy (fluid>100ml/hr, albumin every 6hours and /or 
vasopressor therapy) and a drop in GCS by ≥ 2 points (not due to drug effect), or acute 
change of neurological status related to cerebral vasospasm. Also, patients were 
considered to have clinical vasospasm if they had radiologic evidence of vasospasm and a 
corresponding drop in GCS. (Figure 2 and 3)  
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Classification of Cerebral Vasospasm 
Cerebral vasospasm has been classified as asymptomatic and symptomatic 
vasospasm. Asymptomatically present (radiological defect only without the happening of 
clinical vasospasm manifestation) or symptomatically present (clinical and radiological 
irregularity or clinical vasospasm only). The combination of radiological (TCD velocity 
or angiography) and clinical diagnosis is a powerful predictor of vasospasm and poor 
outcome. 
 
 
Figure 2: Cerebral Vasospasm Definition 
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Figure 3: Definition of clinical vasospasm 
 
 
Definition of Severe Vasospasm 
 
Patients were to have considered having severe cerebral vasospasm if their 
TCD>200 cm/sec or their angiography report stated severe vasospasm. (Figure 4) 
 
Figure 4: Severe cerebral vasospasm definition 
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Outcome Measures 
  The primary outcome end point was the incidence of cerebral vasospasm. The 
secondary outcome end points were incidence of symptomatic and asymptomatic 
vasospasm, length of triple H therapy, incidence of severe vasospasm, mortality, length 
of hospital stay, and survivor discharge disposition (rehabilitation, home, skilled facility). 
(Figure 5) 
 
Figure 5: Discharge disposition stratification 
 
Sample Size Calculation  
Our sample size calculation was built on a binomial model.  From the Lynch et al 
study, the incidence of vasospasm with control was 60% and with simvastatin was 26%. 
Using nQuery Advisor software, a two-group continuity corrected χ2 test with a 0.05 
two-sided significance level would have 80% power to detect the difference between a 
23 
 
 
 
Group 1 proportion, π, of 0.60 and a Group 2 proportion, π, of 0.26 (odd ratio of 4.269) 
when the sample size in each group is 38. Therefore, based on our calculation, the 
minimum sample size in each arm is 38. 
 
Statistical Analysis 
The baseline demographics and the clinical characteristics of the study population 
were described by frequencies, chi square, mean, and standard deviation. The 
significance of differences in continuous variables was performed using the Student t-test 
for normally distributed data. The Wilcoxon rank-sum test was used for continous data 
that was not normally distributed data. Frequencies were analyzed using the chi-square 
test. We compared the demographic and clinical characteristics of the subjects on 
admission between the two treatment groups and all baseline demographics were tested 
for univariate associations. They were considered statistically significant when the P 
value was <0.05. P values were 2-sided. The association of pravastatin therapy with 
incidence of cerebral vasospasm and the secondary outcomes were analyzed using 
logistic regression to identify factors that may have affected the outcome. The adjustment 
plan was for the following covariates: patient age, gender, race, WFNS grade, Hunt and 
Hess grade, Fisher grade, Hunt and Hess, history of hypertension, other cardiovascular 
disease, other probable conditions causing neurological deterioration (e.g., 
hydrocephalus, intracerebral hemorrhage, intraventricular bleeding and intraparenchymal 
bleeding, subdural hemorrhage, and hyponatremia), tobacco use, excessive alcohol 
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intake, history of cocaine use, clinical condition on admission and before surgery, 
aneurysm location; and timing of aneurysm surgery. Univariate analysis was performed 
to determine the variables that predicted our outcome (vasospasm). To control for 
potential interaction among variables, a logistic regression model was created. We 
identified demographic, clinical, and determined the strength of association of vasospasm 
with the use of pravastatin, examined associations with hospital length of stay, mortality, 
and discharge disposition.  All analyses were performed using JMP Version 8 (latest 
version).  
 
Screening and Building the Multivariate Model 
Choosing which variables to take in a model is not clear, especially in the case 
aSAH. For the purpose of building a multivariable model, we have chosen to include the 
risk factor and possible confounding variables that have been shown in past studies to be 
confounders. We tried not to be strict in including the relevant variables in the analysis; 
and we excluded any irrelevant factors or any factors that were not directly connected to 
vasospasm. We also excluded variables with more than 8 missing data. We first ran 
explanatory steps in order to describe the association of each predictor to the outcome 
variable (vasospasm) and to avoid the possibility of having variables that were weakly 
associated with the outcome when examined individually, but were strongly related with 
outcome when examined together. The entrance criteria were p-value ≤ 0.2. Then we 
tried to decrease the number of variables in order to obtain a simple final model by using 
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automatic variable selection analysis (Forward stepwise regression building analysis) 
with entry criteria of significance level at 0.2. Then we summarized the results of the 
analysis with statistically significant variables (race, clipping, WFNS score, and elevated 
WBC) in the model. 
 
Interaction and Lack of Fit Test 
The lack of fit test for this multivariate’s model was used to determine if higher order 
model is indicated. If the lack of fit test for this multivariate’s model is statistically 
significant, then higher order model is indicated. 
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CHAPTER 3 RESULTS 
 
Demographics and Clinical Characteristics 
The total number of study patients was 81. A total of 42 patients were included in 
the NP group, and 39 patients were included in the PRAV group (pravastatin 40mg). 
(Figure 3) Descriptive demographic data and clinical characteristics of our sample are 
listed in Table 6.  We tested for the difference of our covariates across the PRAV and the 
NP groups to examine if the two groups were different at baseline. Approximately 80% 
(n= 65) of our sample was female. The proportion of female patients was not statistically 
different between the groups. Approximately 60% (n= 49) of our sample was African 
American. The mean of age was 51 years (SD= 12.1) and approximately 55% (n= 45) 
were less than age 55.  Sixty-two percent of our sample (n= 50) were admitted with 
WFNS grade 1 or 2, and 60% (n= 48) had a history of hypertension. Ninety percent of 
our sample were clipped or coiled. The time to surgery was less than 72 hours for 98% 
(n= 70) of patients who had surgery. Between the two treatment groups, there was no 
statistically significant difference in the mean age. In addition, there was no statistically 
significant difference in the proportions of the following covariates: gender, race, WFNS 
grade, severity grades, history of tobacco, cocaine use, alcohol use, elevated WBC, 
hypomagnesemia, hyponatremia, hypertension, hydrocephalus, myocardial infarction, 
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seizure, intraparenchymal hemorrhage, intracerebral hemorrhage, intraventricular 
hemorrhage, subdural hemorrhage, atrial fibrillation, anemia, or heart failure.
However, there was statistically significant difference between the groups in regards to 
type of surgery, troponin-I, elevated WBC, and number of comorbidities. The proportion 
of clipped patients and the proportion of patients with elevated troponin-I on admission 
were significantly higher in the NP group versus the PRAV group (P <0.0001, P= 0.0028 
respectively). The proportion of patients who had more than one comorbidity and the 
proportion of patients who had surgery after 72 hours or had no surgery were 
significantly higher in the PRAV group versus NP group (P=0.006, P=0.002, 
respectively) (Figure 6) 
 
Figure 6: Enrollment Flow Diagram 
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Medians of GCS scores at Admission between the Two Treatment Groups 
The median of GCS score in the two treatment groups was 14 (Range 3-15) in NP 
versus 15 (Range 3-15) in PRAV. Using Wilcoxon test, there was no statistically 
significant difference in the medians of GCS scores across the two treatment groups (P 
=0.391). (Figure 7) 
 
Figure 7: Difference of Median of GCS scores across the Two Groups 
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Table 6: Descriptive Demographics and Clinical Characteristics 
 PRAV NP  
 Count % Count % N X2 P 
Gender        
Female 31 80 34 81 65 0.027 0.869 
Male 8 20 8 19 16   
Race         
African American (AA) 22 56 27 64 49 0.525 0.469 
Non- AA* 17 44 15 36 32   
Co-morbidities        
0 or 1 16 41 30 71 46 7.735 0.006 
>1 23 59 12 29 35   
WFNS        
I or II 27 69 23 55 50 1.792 0.181 
III-V 12 31 19 45 31   
Severitya        
Minor to Moderate 6 16 5 19 11 0.224 0.809 
Major- Extreme 31 84 22 81 53   
Tobaccoa        
Y 22 63 25 64 47 0.012 0.912 
N 13 37 14 36 27   
Cocainea        
Y 3 9 2 6 5 0.156 0.693 
N 31 91 30 94 61   
Alcohola        
Y 16 46 17 46 33 0.000 0.984 
N 19 54 20 54 39   
Aneurysm Location        
Anterior 33 85 38 90 71 0.642 0.423 
Posterior 6 15 4 10 10   
Clipped        
Yb 20 51 41 98 61 23.350 <0.0001 
Nc 19 49 1 2 20   
Time to Surgery        
<72hrs 29 74 41 98 70 9.322 0.002 
>72hrs or no surgeryc 10 26 1 2 11   
Elevated WBC        
Y 34 87 36 86 70 0.037 0.848 
N 5 13 6 14 11   
Elevated Troponin-Ia        
Y 7 25 17 65 24 8.905 0.002 
N 21 75 9 35 30   
Hypomagnesemia        
Y 0 0 1 2 1 0.940 0.332 
N 39 100 41 98 80   
Hyponatremia        
Y 10 26 7 17 17 0.982 0.321 
N 29 74 35 83 64   
Hypertension        
Y 27 69 21 50 48 3.098 0.078 
N 12 31 21 50 33   
Hydrocephalus        
Y 11 28 11 26 22 0.041 0.839 
N 28 72 31 74 59   
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Diabetes Mellitus 
Y 8 20 4 10 12 1.935 0.164 
N 31 80 38 90 69   
Myocardial Infarction         
Y 2 5 5 12 7 1.176 0.278 
N 37 95 37 88 74   
Seizure        
Y 9 23 6 14 15 1.036 0.309 
N 30 77 36 86 66   
Intraparenchymal 
Hemorrhage 
       
Y 2 5 2 5 4 0.006 0.939 
N 37 95 40 95 77   
Intracerebral 
Hemorrhage 
       
Y 4 10 1 2 5 2.166 0.141 
N 35 90 41 98 76   
Intraventricular 
Hemorrhage 
       
Y 5 13 2 5 7 1.663 0.197 
N 34 87 40 95 74   
Subdural Hemorrhage        
Y 0 0 1 2 1 0.940 0.332 
N 39 100 41 98 80   
Atrial Fibrillation        
Y 2 5 2 5 4 0.006 0.939 
N 37 95 40 95 77   
Anemia        
Y 5 13 1 2 6 3.080 0.073 
N 34 87 41 98 75   
Heart Failure         
Y 2 5 0 0 2 2.208 0.137 
N 37 95 42 100 79   
Age Mean SD Mean SD  t-test p-value 
 53.20 10.81 49.59 13.07 81 8.902 0.179 
        
 
* Three were Hispanic, one was other and 28 were Caucasians 
a Variable had missing data 
b 8 patients were clipped and coiled during the same admission 
c There were 9 patients had no surgery 
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The Crude Analysis of the Effect of Pravastatin 40mg on the Incidence of Cerebral 
Vasospasm 
Approximately 75% (n= 60) of our study patients experienced cerebral 
vasospasm. In the NP group 88% experienced vasospasm and in the PRAV group 59% 
experienced vasospasm. (Table 7, Figure 8.) Using Pearson chi-square test, there was a 
statistically significant difference in the proportion of cerebral vasospasm between the 
two groups (P =0.0028), with the NP group having a significantly higher incidence of 
cerebral vasospasm.  
Table 7: Cerebral Vasospasm by Treatment Groups 
 
 VSP No VSP Total
NP 37 
(88%) 
5
(12%)
42
PRAV 23 
(59%) 
16
(41%)
39
 60 21 81
 
 
 
n= 5
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0%
20%
40%
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80%
100%
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No VSP
VSP
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Figure 8: Incidence of Vasospasm between the Treatment Groups 
 
Incidence of Vasospasm Stratified by Duration of Pravastatin Use  
The mean duration of pravastatin use was 13.80 days (± 6.338) and the median 
was 12 days (range 19 days). The percentage of patients who completed 20 or 21 days of 
pravastatin 40mg daily was 36% (n= 14). Using t-test, there was no association between 
the duration of pravastatin use and the incidence of vasospasm in the PRAV group 
(P=0.263). We also categorized the duration of use into two categories (14 days or less 
and 15-21 days of pravastatin use) in order to test the difference between the two periods; 
46% (n= 18) were in the 15-21 day period. Using Pearson chi-square test, there was no 
statistically significant difference in the incidence of cerebral vasospasm between the two 
periods (P=0.37). (Table 8, Figure 9.) 
Table 8: Incidence of Vasospasm by  
Categories of Duration of Pravastatin Use  
 
 VSP No VSP Total
15-21 12 
(67%) 
6
(33%)
18
<14 11 
(52%) 
10
(48%)
21
 23 16 39
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Figure 9: Incidence of Vasospasm Stratified by Duration of Pravastatin Use  
 
Clinical and Radiological Vasospasm Diagnosis Stratification 
 
Sixty-four percent (n=52) of the study patients experienced clinical symptoms of 
vasospasm; 70% (n= 36) of them were among the NP group. The overall stratification of 
vasospasm diagnosis can be found in Figure 10. The clinical vasospasm diagnosis 
stratification can be found in Figure 11. The radiological vasospasm diagnosis 
stratification can be found in Figure 12. 
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Table 9: Symptomatic and Asymptomatic VSP by Treatment Groups 
 
 Asymptomatic Symptomatic Total
NP 1 
(3%) 
36
(97%)
37
PRAV 7 
(30%) 
16
(70%)
23
 8 52 60
 
 
 
 
 
Figure 13: Symptomatic and Asymptomatic Vasospasm by Treatment Groups  
 
Results of Screening and Building the Multivariate Model 
The Association of Cerebral Vasospasm and Potential Covariates 
The characteristics of patients, based on whether or not they experienced 
vasospasm are described in Table 10. Some variables were not included in the 
multivariate model because they did not meet the criteria of being associated at a P value 
less than 0.2 (Table 10). The ones that did meet these criteria were included in a 
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multivariate regression model with vasospasm as the outcomes variable. The predictors 
tested were race, clipped, elevated WBC, elevated troponin-I, hydrocephalus, and the 
pravastatin treatment group. We included WFNS because it is correlated with aSAH 
outcomes. 
Table 10: Primary Outcome Univariate Analysis 
 
 Vasospasm No-Vasospasm  
 Count % Count % N X2 P 
Gender        
Female 47 78 18 86 65 0.535 0.465 
Male 13 22 3 14 16   
Race        
African American (AA) 39 65 10 48 49 1.966 0.161 
Non-AA* 21 35 11 52 32   
Co-morbidities        
0 or 1 35 58 11 52 46 0.225 0.636 
>1 25 42 10 48 35   
WFNS        
I or II 35 58 15 71 50 1.863 0.394 
III-V 25 42 6 29 31   
Severitya        
Minor to Moderate 7 16 4 20 11 2.171 0.367 
Major- Extreme 37 84 16 80 53   
Tobaccoa        
Y 35 64 12 63 47 0.001 0.970 
N 20 36 7 37 27   
Cocainea        
Y 4 8 1 6 5 0.144 0.704 
N 44 92 17 92 61   
Alcohola        
Y 25 48 8 40 33 0.350 0.538 
N 27 52 12 60 39   
Aneurysm Location        
Anterior 45 90 17 81 71 1.177 0.278 
Posterior 6 10 4 19 10   
Clippedb        
Y 51 85 10 48 61 11.690 0.001 
Nc 9 15 11 52 20   
Time to Surgery        
<72 hrs 56 93 13 62 69 0.386 0.535 
>72 hrs or no surgeryc 4 7 8 38 12   
Elevated WBC        
Y 55 92 15 71 70 5.429 0.020 
N 5 8 6 29 11   
Elevated Troponin-Ia        
Y 21 51 3 23 24 3.166 0.075 
N 20 49 10 77 30   
Hypomagnesaemia        
Y 1 2 0 0 1 0.354 0.552 
N 59 98 21 100 80   
Hyponatremia        
Y 11 18 6 29 17 0.983 0.321 
N 49 82 15 71 46   
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Hypertension        
Y 34 57 14 67 48 0.644 0.422 
N 26 43 7 33 33   
Hydrocephalus         
Y 19 32 3 14 22 0.041 0.123 
N 41 68 18 86 59   
Diabetes Mellitus        
Y 10 17 2 10 12 0.629 0.428 
N 50 83 19 90 69   
Myocardial Infarction        
Y 6 10 1 5 7 0.541 0.462 
N 54 90 20 95 74   
Seizure        
Y 13 22 2 10 15 1.520 0.218 
N 47 78 19 90 66   
Intraparenchymal 
Hemorrhage 
       
Y 3 5 1 5 4 0.002 0.965 
N 57 95 20 95 77   
Intracerebral Hemorrhage        
Y 3 5 2 10 5 0.550 0.459 
N 57 95 19 90 76   
Intraventricular 
Hemorrhage 
       
Y 4 7 3 14 7 1.144 0.285 
N 56 93 18 86 74   
Subdural Hemorrhage        
Y 1 2 0 0 1 0.354 0.552 
N 59 98 21 100 80   
Atrial Fibrillation        
Y 3 5 1 5 4 0.002 0.965 
N 57 95 20 95 77   
Anemia        
Y 3 5 3 14 6 3.080 0.162 
N 57 95 18 86 75   
Heart Failure        
Y 1 2 1 5 2 0.619 0.432 
N 59 98 20 95 79   
Pravastatin 40mg        
Y 23 38 16 76 39 8.930 0.0028 
N 37 62 5 24 42   
Age at arrival Mean SD Mean SD  t-test p-value 
 50.46 12.69 53.83 10.08 81 8.902 0.226 
 
* Three were Hispanic, one was other and 28 were Caucasians 
a. Variable had missing data 
b. 8 patients were clipped and coiled at the same admission 
c. There were 9 patients that had no surgery 
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A multivariate analysis was conducted, adjusting for the following covariates: race, 
WFNS, elevated WBC, and aneurysm clipping. (Table 11) 
Table 11: Results of the Multivariate Logistic Regression Analysis of the Predictors 
of Cerebral Vasospasm following SAH 
 
Variable 
 
Chi Square Odd ratio Lower CI Upper CI 
 
p-value 
 
Pravastatin 
 
3.014 
 
0.278 0.058 1.180 
 
0.082 
 
Race (non- AA*) 
 
1.653 0.453 0.130 1.519 
 
0.198 
 
Elevated WBC 
 
5.174 
 
6.140 1.284 34.605 
 
0.023 
 
Clipped 
 
1.941 2.690 0.668 11.336 
 
0.163 
 
WFNS ( III-V) 
 
0.462 1.565 0.434 6.184 
 
0.496 
*AA=African American 
The logistic regression model showed no statistically significant difference in the 
proportion of cerebral vasospasm across the two treatment groups (P=0.082). The odds of 
developing vasospasm in the PRAV group were less than the NP group, but it was not 
statistically significant. The odds of having vasospasm in Non- African American 
patients were less than the African American patients, but it was not statistically 
significant. Patients with elevated WBC counts had a 6-fold increase in the odds of 
developing vasospasm. Furthermore, the odds of developing vasospasm in clipped 
patients were higher than non-clipped patients, but it was not statistically significant. The 
odds of developing vasospasm in patients with WFNS scores of III-V were higher than 
patients with WFNS scores of I-II, but it was not statistically significant. 
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Interaction and Lack of Fit Test 
Since the lack of fit test for this multivariate’s model was not statistical 
significant, no higher order model is indicated. 
 
Multivariate Analysis Model without Including Clipping Surgery 
Because of collinearity (98% of NP group were clipped) and in order to check 
which variable has the most impact on vasospasm, we reran the analysis without 
including the clipping as a covariate. A multivariate nominal logistic regression was fit 
with effects of race, WFNS, and elevated WBC. (Table 12) The logistic regression model 
showed a statistically significant difference in the proportion of cerebral vasospasm 
across the two groups (PRAV and NP) (p=0.005) when clipping was removed from the 
model. The proportion having cerebral vasospasm was lower in the pravastatin group.   
However, the p-value for pravastatin 40mg effect on reducing vasospasm remained 
insignificant when any of the following covariates were removed: elevated WBC, WFNS, 
non-African-American race in the presence of clipping effect.   
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Table 12: Multivariate Analysis Model without Including Clipping Surgery 
 
Variable 
 
Chi Square Odd ratio Lower CI Upper CI 
 
P-value 
 
Pravastatin 
 
9.448 
 
0.164 0.041 0.535 
 
0.002 
 
Race (non-AA*) 
 
2.560 0.389 0.115 1.236 
 
0.110 
 
Elev. WBC 
 
6.464 
 
7.150 1.565 39.173 
 
0.011 
 
WFNS (III-V) 
 
0.398 
 
1.494 0.432 5.595 
 
0.528 
*AA=African American 
 
Incidence of Vasospasm in the Clipped Patients   
Using Pearson chi-square test, in the clipped patients, there was no statistically 
significant difference in the proportion of vasospasm between in the two treatment groups 
(p=0.21). (Table 13 and Figure 14) 
 
 
Table 13: Cerebral Vasospasm in Clipped Patients 
 
 VSP No VSP Total
NP 36 
(88%) 
5 
(12%) 
41
PRAV 15 
(75%) 
5 
(25%) 
20
 51 10 61
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Figure 14: Incidence of Vasospasm in Clipped Patients   
 
Incidence of Vasospasm in the Non-Clipped Patients   
Using Pearson chi-square test, in the non-clipped patients, there was no 
statistically significant difference in the proportion of vasospasm between the two groups 
(p=0.257). (Table 14 and Figure 15) 
  
Table 14: Cerebral Vasospasm in Non-Clipped patients 
 
 VSP No VSP Total
NP 1 
(100%) 
0 
(0%) 
1
PRAV 8 
(42%) 
11 
(58%) 
19
 9 11 20
 
n=36
n=15
65%
70%
75%
80%
85%
90%
NP (N=41) PRAV (N=20)
Treatment Groups
P=0.21
Incidence of Vasospasm in Clipped Patients 
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Figure 15: Incidence of Vasospasm in Non-Clipped Patients 
 
 
Incidence of Vasospasm by Type of Surgical Intervention in the PRAV Patients  
 
Using Pearson chi-square test, among the pravastatin users, the proportion of 
patients experiencing vasospasm was significantly higher in the clipped group as 
compared to non-clipped group(p=0.037). (Table 15 and Figure 16) 
 
 
Table 15: Cerebral Vasospasm by Type of  
Surgical Intervention in the PRAV Patients 
  
 VSP No VSP Total
Non-Clipped 8 
(42%) 
11
(58%)
19
Clipped 15 
(75%) 
5
(25%)
20
 23 16 39
n=1
n=8
0%
20%
40%
60%
80%
100%
120%
NP (N=1) PRAV (N=19)
Treatment Groups
P=0.257
Incidence of Vasospasm in Non‐Clipped Patients 
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Figure 16: Vasospasm across Surgical Intervention Groups in the PRAV Group 
 
Radiological Confirmation of Vasospasm 
Approximately 64% (n=52) of our study patients had radiological confirmation of 
vasospasm; 62 % (n=32) were in the NP group. Among vasospasm patients, there was no 
statistically significant difference in the proportion of patients who had radiological 
confirmation of vasospasm among the two treatment groups (P=0.959). (Table 16, Figure 
17.) 
Table 16: Radiological Confirmation of VSP by Treatment Groups 
 N Y Total
NP 5 
(14%) 
32 
(86%) 
37
PRAV 3 
(13%) 
20 
(87%) 
23
 8 52 60
 
n=8
n=15
0%
20%
40%
60%
80%
Non‐Clipped Clipped
Surgical Intervention Groups
P=0.037
Incidence of Vasospasm by Type of Surgical 
Intervention in the PRAV Patients 
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Figure 17: Incidence of Radiologically Confirmed Vasospasm by Treatment Groups  
 
Elevated TCD Velocity (≥120 or Double Baseline) 
Approximately 66% (n=45) of our study patients experienced elevated TCD 
reading ≥120 cm/sec or had their TCD velocity double from baseline during 
hospitalization; 64% (n=29) of them were in the NP group. Using Pearson chi-square test, 
among the vasospasm patients, there was no statistically significant difference in the 
proportion of patients who had elevated TCD velocity between the two groups (P= 
0.614). (Table 17, Figure 18.)  
 
 
 
 
n=32 n=20
75%
80%
85%
90%
95%
100%
NP(N=37) PRAV (N=23)
Treatment Groups
P=0.959
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Treatment Groups
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Table 17: Elevated TCD Velocity by Treatment Groups 
 
N Y Total
NP 5 
(15%) 
29 
(85%) 
34
PRAV 4 
(20%) 
16 
(80%) 
20
 
9 45 54
 
 
Figure 18: Vasospasm Patients with Elevated TCD Velocity 
 
Vasospasm by Angiography Report 
Approximately, 35% (n=28) of our study patients had evidence of cerebral 
vasospasm documented in their angiography reports; approximately 68% (n=19) of them 
were in the NP group. Using Pearson chi-square test, among the vasospasm patients, 
there was no statistically significant difference in the proportion of patient who had 
n=29 n=16
0%
20%
40%
60%
80%
100%
NP (N=34) PRAV (N=20)
Treatment Groups
P=0.614
Incidence of Elevated TCD between the Treatment 
groups among Vasospasm Patients
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vasospasm documented in their angiography report between the two treatment groups 
(P=0.356). (Table 18, Figure 19.) 
  
Table 18: Angiographic VSP by Treatment Groups 
 
 N Y Total
NP 18 
(49%) 
19 
(51%) 
37
PRAV 14 
(61%) 
9 
(39%) 
23
 32 28 60
 
 
Figure 19: Angiographically Confirmed Vasospasm by Treatment Groups  
 
Glasgow Coma Scale (GCS) Score Decline  
Sixty-five percent (n=53) of the study patients experienced a drop in GCS by two 
points or more; 70 % (n=37) of them were in the NP group.  Using Pearson chi-square 
test, among the vasospasm patients there was a statistically significant difference in the 
n=19
n=9
0%
10%
20%
30%
40%
50%
60%
NP (N=37) PRAV (N=23)
Treatment Groups
P=0.356
Angiographically Confirmed Vasospasm by 
Treatment Groups
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proportion of patient who had a GCS drop between the two groups. The proportion of 
GCS drop was significantly higher in the NP group (P=0.001). (Table 19, Figure 20) 
 
Table 19: Decline in GCS by Treatment Groups 
in Vasospasm Patients 
 
 N Y Total
NP 2 
(5%) 
35 
(95%) 
37
PRAV 9 
(39%) 
14 
(61%) 
23
 11 49 60
 
 
Figure 20: GCS Decline ≥ 2 Points by Treatment Groups in Vasospasm Patients  
 
Triple H Therapy Use  
Approximately 53% (n=43) of the study patients received triple H therapy; 74% 
(n=32) of them were in the NP group. Using Pearson chi-square test, among the 
n=35
n=14
0%
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80%
100%
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vasospasm patients, the proportion of triple H therapy use was significantly higher in the 
NP group (P=0.0012). (Table 20, Figure 21.) 
 
Table 20: Use of Triple H by Treatment Groups 
 
 N Y Total
NP 5 
(14%) 
32 
(86%) 
37
PRAV 12 
(52%) 
11 
(48%) 
23
 17 43 60
 
 
 
 
Figure 21: Use of Triple H Therapy among Vasospasm Patients  
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Number of Days to Start of Triple H Therapy across the Treatment Groups  
The mean number of days to triple H therapy was 3.9 days (± SD=2.82). 
Using Wilcoxon test, the median number of days from admission to triple H therapy was 
significantly higher in the NP group (median=3 [Range 1-15] in NP vs. median=4 [Range 
2-8] in PRAV, P=0.0438). (Figure 22) 
 
Figure 22: Number of Days from Admission to Start of Triple H Therapy  
 
Duration of Triple H Therapy across the Two Treatment Groups  
The mean of duration of triple H therapy was 6.5 days (SD±3.92). Using 
Wilcoxon test, there was no statistical significant difference in the median duration of 
triple H therapy across the two groups (median=6.5 [Range 1-18] in NP vs. median=6 
[Range 1-8] in PRAV, P=0.121). (Figure 23) 
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Figure 23: Duration of Triple H Therapy  
 
Screening and Building the Multivariate Models for Secondary Outcomes 
In order to adjust for all potential cofounder effects on the relationship of 
pravastatin on the secondary outcomes (mortality, LOS, discharge disposition, and 
incidence of radiological severe vasospasm) we built a multivariate model using the same 
methodology and statistical strategy we used for the primary outcome (cerebral 
vasospasm). We first ran explanatory steps to describe the association of each predictor to 
the outcome variables. The entrance criterion was a p-value = 0.2 and we exclude any 
variable with p-value > 0.20. Then we tried to decrease the number of variables in order 
to obtain a simple final model by using automatic variable selection analysis (forward 
stepwise regression building analysis) with entry criteria of a significance level at 0.2. 
Then we reran the analysis with the remaining selected statistically significant variables 
in the model. No single variable met inclusion criteria for the multivariate model for all 
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the secondary outcomes. However, we built a multivariate analysis for each outcome 
adjusting for the following clinically important risk factors: race, WFNS score, number of 
comorbidities, tobacco use, and clipping surgery. 
 
Mortality 
Approximately 17% (n=14) of our study patients expired during hospitalization; 
64% (n=9) of them were in the PRAV group. Using Pearson chi-square test, there was no 
statistically significant difference in mortality between the two treatment groups (P = 
0.184). (Table 21 and 22, Figure 24.) 
 
Table 21: Mortality  
 
 Expired Alive Total
NP  5 
(12%) 
37
(88%)
42
PRAV 9 
(23%) 
30
(77%)
39
 14 67 81
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Figure 24: Mortality across the Two Treatment Groups 
 
Table 22: Results of the Multivariate Logistic Regression Analysis of the Predictors 
of Mortality following aSAH 
 
Variable 
 
Chi Square Odds Ratio Lower 95% 
 
Upper 95% 
 
p-value 
 
Pravastatin 
 
0.539 2.190 0.262 21.285 
 
0.463 
 
Race (non-AA*) 
 
0.029 1.122 0.221 5.540 
 
0.885 
 
WFNS( III-V) 
 
0.186 0.664 0.078 3.999 
 
0.666 
 
No. of Co-
morbid.(0 or 1) 
 
 
0.062 0.809 0.147 4.419 
 
 
0.803 
 
Clipped 
 
1.752 0.305 0.044 1.761 
 
0.186 
 
Tobacco use 
 
0.107 1.299 0.280 7.286 
 
0.743 
*AA=African American 
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The logistic regression model showed no statistically significant difference in 
mortality across the two treatment groups. (Table 22) The odds of death in the PRAV 
group were higher than the NP group, but it was not statistically significant. None of the 
other variable had an association with mortality.  (Table 22)  
 
Discharge Disposition  
Overall discharge disposition by treatment group can be found in Table 23 and 
Figure 25. Of the survivors, approximately 57% (n=46) of our patients were discharged 
to home; 63% (n=29) of them were in the PRAV group. Using Pearson chi-square test, 
among the vasospasm patients, the proportion of patients discharged to home was higher 
in the PRAV group P <0.0001. (Table 24, Figure 26.) 
 
Table 23: Overall Discharge Disposition  
 
 Other Home Expired Total
NP 20 
(48%) 
17 
(40%) 
5
(12%)
42
PRAV 1 
(3%) 
29 
(74%) 
9
(23%)
39
 21 46 14 81
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Figure 25: Overall Discharge Disposition in the Treatment Groups among All 
Patients  
 
 
Table 24: Survivors Discharge Disposition in 
Vasospasm Patients 
 
 Other Home Total
NP 20 
(63%) 
12 
(37%) 
32
PRAV 1 
(5%) 
18 
(95%) 
19
 21 30 51
 
n=17
n=29
n=20
n=1
n=5
n=9
0%
10%
20%
30%
40%
50%
60%
70%
80%
NP (N=42) PRAV (N=39)
Treatment Groups
P <0.0001
Overall Discharge Disposition
Home
Other
Expired
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Figure 26: Survivors Discharge Disposition in Vasospasm Patients  
 
 
 
Table 25: Results of the Multivariate Logistic Regression Analysis of the Predictors 
of Home Discharge Disposition Following SAH 
Variable  
Chi Square 
Odds 
Ratio Lower 95% Upper 95% p-value 
 
Pravastatin 
 
26.703 365.466 22.511 21676.85 
 
<.0001 
 
No. of Co-morbid.(0 
or 1) 
 
 
7.133 21.515 2.129 578.246 
 
 
0.008 
 
Clipped 
 
0.289 0.281 0.002 24.337 
 
0.590 
 
Race (non-AA*) 
 
2.713 0.239 0.035 1.307 
 
0.099 
 
WFNS(III-V) 
 
6.127 0.113 0.013 0.647 
 
0.013 
*AA=African American 
 
The logistic regression model showed a statistically significant difference in the 
proportion of cerebral vasospasm across the two treatment groups. The odds of being 
discharged to home in the PRAV group were significantly higher than the NP group. The 
n=12
n=18
n=20
n=1
0%
20%
40%
60%
80%
100%
NP (N=32) PRAV (N=19)
Treatment Groups
P <0.0001
Survivors Discharge Disposition in Vasospasm Patients
Home
Other
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odds of having home discharge disposition in patient with 0-1 comorbidity were 
significantly higher than patients with > 1 comorbidities. The odds of being discharged to 
home in patients with WFNS scores of III-V were significantly less than patients with 
WFNS scores of I-II. None of the other variable had an association with mortality.  
(Table 25)  
 
Table 26: Results of the Multivariate Logistic Regression Analysis of the Predictors 
of Home Discharge Disposition among Vasospasm Patients Following aSAH 
 
Variable 
 
Chi Square Odds Ratio Lower 95% Upper 95% 
 
p-value 
 
Pravastatin 
 
16.299 43.963 5.529 1116.551 
 
<.0001 
 
Clipped 
 
0.045 0.677 0.0147 32.265 
 
0.832 
 
WFNS (III-V) 
 
 
9.182 0.091 0.011 0.451 
 
 
0.002 
Race (non-AA*)  
0.802 0.483 0.089 2.382 
 
0.370 
 
*AA=African American 
 
Hospital Length of Stay (LOS) 
The overall mean of length of stay for our study patients was 22.2 (SD± 22.08) 
days, and the median was 15.3 (range was 3-129) days. Using Wilcoxon test, there was 
no statistically significant difference in the median length of stay across the two treatment 
groups; however, there was a trend toward a decreased length of stay in the PRAV group 
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(median=16.8 [range 4.6-122.9] in NP vs. median=12.1 [range 3-129] in PRAV, 
P=0.061). (Figure 27) 
 
Figure 27: Hospital Length of Stay (LOS) 
 
Table 27: Results of the Multivariate Logistic Regression Analysis of the Predictors 
of Shorter LOS Following aSAH 
Variable p-value (Shorter LOS)
Pravastatin 0.064
Race[non-AA*] 0.467
WFNS[I or II] 0.005
No. of Co-
morbid.[0 or 1] 
0.019
Clipped 0.448
Tobacco use 0.278
Elevated WBC 0.396
*AA=African American 
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The logistic regression model showed a statistically significant difference in the 
LOS across the two treatment groups. The LOS was shorter in PRAV group than the NP 
group. Linear multivariate regression analysis showed that patients with WFNS scores of 
III-V (poorer clinical status on admission) had a longer hospital LOS, and patients with 0 
-1 comorbidity had a shorter hospital LOS as reflected by their association with in the 
multivariate analysis. None of the other variable had association with mortality. (Table 
27) 
Neuroscience Intensive Care Unit Length of Stay (NSICU-LOS) 
The overall mean NSICU-LOS was 13.5 (SD±8.72) days, and median was 11.1 
(range 2.2-49.4) days. Using Wilcoxon test, there was no statistically significant 
difference in the mean NSICU-LOS across the two treatment groups (median=13.1 
[range 2.2-49.4] in NP vs. median= 10.1 [range 3-45] in PRAV, P=0.092). (Figure 28) 
 
Figure 28: Neuroscience Intensive Care Unit Length of Stay (NSICU-LOS) 
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Incidence of Severe Radiological Vasospasm 
Approximately 20% (n= 16) of our sample experienced severe vasospasm; 69% 
(n=11) were in the NP group. Using Pearson chi-square test, among the vasospasm 
patients, there was no statistically significant difference in the proportion of severe 
radiological vasospasm between the two treatment groups (P=0.463). (Table 28, Figure 
29.) 
Table 28: Severe Vasospasm by Treatment Groups 
 
 N Y Total
NP 26 
(70%) 
11 
(30%) 
37
PRAV 18 
(78%) 
5 
(22%) 
23
 44 16 60
 
 
Figure 29: Incidence of Severe Radiological Vasospasm  
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Table 29: Results of the Multivariate Logistic Regression Analysis of the Predictors 
of Incidence of Radiological Severe Vasospasm Following aSAH 
 
Variable Chi Square Odds Ratio Lower 95% Upper 95% 
 
p-value 
 
Pravastatin 
 
0.051 0.839 0.171 3.796 
 
0.821 
 
Race (non-AA*) 
 
0.194 0.751 0.195 2.627 
 
0.660 
 
No. of Co-
morbid.(0 or 1) 
 
 
0.044 1.163 0.285 4.992 
 
 
0.834 
 
WFNS (3-5) 
 
1.486 2.290 0.605 9.262 
 
0.223 
 
Clipped 
 
0.006 0.976 0.152 8.133 
 
0.980 
*AA=African American 
The logistic regression model showed no statistically significant difference in the 
incidence of radiological severe vasospasm across the two treatment groups. (Table 29) 
The odds of developing radiological severe vasospasm in the PRAV group were lower 
than the NP group, but it was not statistically significant. None of the other variable had 
association with the incidence of radiological severe vasospasm. (Table 30) 
 
Association of Cerebral Vasospasm with Mortality 
Fourteen patients expired during hospitalization and approximately 64% (n=9) 
experienced cerebral vasospasm. Using Pearson chi-square test, there was no statistically 
significant difference in mortality based on vasospasm occurrence (p=0.358). (Table 30, 
Figure 30.)  
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Table 30: Mortality between Cerebral Vasospasm Groups 
 
 Expired Alive Total
VSP 9 
(15%) 
51 
(85%) 
60
No VSP 5 
(24%) 
16 
(76%) 
21
 14 67 81
 
 
Figure 30: Mortality across the Two Vasospasm Groups 
 
Association of Cerebral Vasospasm with Discharge Disposition Outcome 
One hundred percent (n=21) of survivors who were discharged to facility other 
than home (rehabilitation, skilled nursing facility) experienced cerebral vasospasm. Using 
Pearson chi-square test, the proportion of patients who were discharged to home was 
significantly higher in the no-vasospasm group (p=0.002). The proportion of patients who 
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were discharged to a facility other than home was significantly higher in the vasospasm 
group. (Table 31, Figure 31.) 
Table 31: Survivors’ Discharge Disposition by Cerebral Vasospasm  
 Other Home Total
VSP 21 
(41%) 
30 
(59%) 
51
No VSP 0 
(0%) 
16 
(100%) 
16
 21 46 67
 
 
Figure 31: Survivors’ Discharge Disposition across the Vasospasm Groups 
 
Association of Cerebral Vasospasm with Hospital Length of Stay 
Using Wilcoxon test, the median length of stay in the vasospasm group was 
significantly higher than the no-vasospasm group (median=16.5 [range 3-129] in 
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vasospasm group versus median=11.1 [Range 3-56.4] in no-vasospasm group, P=0.028). 
(Figure 32)   
 
Figure 32: Cerebral Vasospasm and Hospital Length of Stay 
 
Association of Cerebral Vasospasm with Neuroscience Intensive Care Unit Length of 
Stay (NSICU-LOS) 
Using Wilcoxon test, the median of NSICU-LOS was significantly higher in the 
vasospasm group (median=13.2 [range 3-49.4] in vasospasm group versus median=5.7 
[Range 2.2-27] in no-vasospasm group, p=0.0018).  (Figure 33) 
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Figure 33: Neuroscience Intensive Care Unit Length of Stay (NSICU-LOS) by 
Cerebral Vasospasm 
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CHAPTER 4 DISCUSSIONS 
 
The use of statins for prevention and/ or treatment of vasospasm in aSAH patients 
have spread over the past several years and studying statins has been an active area of 
cerebrovascular research.  Statins may help to decrease the incidence of cerebral 
vasospasm due to their role in improving endothelial dysfunction. To date, the use of 
statins for decreasing the incidence of vasospasm after aSAH has been studied in three 
prospective studies and four retrospective studies.  (120-127) These studies differ from 
ours in the characteristics of study population and methods, as well as results they found. 
(Table 32, 33, 34, and 35) 
Only two of the prospective studies showed a decrease in the incidence of 
vasospasm or improved outcomes after aSAH with statins use. (120, 122, 135) The third 
prospective study did not achieve statistical significance. (123) The four published 
retrospective studies examined outcomes in patients who received statin therapy before 
aSAH had contradictory results. Parra and colleagues found that previous statin therapy 
improved functional outcomes after aSAH.(124) Another study by McGirt and colleagues 
found that previous statin therapy for at least one month before aSAH and continued after 
the hemorrhage (for 14 days) decreased the incidence of cerebral vasospasm by 11-
fold.(125)  However, the study by Singhal and colleagues reported an increased risk of 
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vasospasm in patients who had been on statin therapy before aSAH.(126) In addition, 
Kramer and colleagues, recently found that statin therapy was not associated with 
improved outcomes in aSAH patients.(127) 
 In our study, we examined the effects of pravastatin use on the incidence of 
vasospasm and outcomes throughout the admission period after aSAH in a cohort of 39 
aSAH patients taking pravastatin and 42 control subjects. There was no significant 
difference in WFNS scores for each group (P=0.18). The proportion of patients 
undergoing aneurysm clipping was higher in NP group (98% NP vs. 51% PRAV, P 
<0.0001). Approximately 74% of the study patients experienced cerebral vasospasm, of 
which 62% (n= 37) were in the NP group. Vasospasm was observed in 88% of patients 
not taking pravastatin versus 55% taking pravastatin. Eighty five percent of patients had 
symptomatic vasospasm (were diagnosed by radiological and clinical criteria). 
To control for multiple variables, exclude the confounding influence of other 
factors on vasospasm, and to clarify the role of these variables which are known to 
impact the incidence of vasospasm, a logistic regression model was used. Although time 
to surgery, elevated troponin-I, and number of comorbidities differed between the 
treatment groups (intercohort differences), none of them had a significant univariate 
association with vasospasm. They were, therefore, not included in the final multivariable 
models. Variables were chosen from among those that were significant in the univariate 
analysis of vasospasm. Vasospasm was more frequent with elevated WBC, clipping 
surgery, and American African race.  Although WFNS score was not associated with the 
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development of vasospasm in a univariate association, we adjusted for variations in 
WFNS score because it is correlated with outcomes of aSAH. The presence of anemia 
(ICD-9 code for anemia and 2 consecutive hemoglobin concentrations <10 g/dl) was 
removed from the regression model as only a few patients were anemic by our definition 
(n = 6) and because triple H therapy is used to induce hemodilution in aSAH patients 
which would confound this variable.   
The crude analysis showed that pravastatin was associated with a decrease in the 
incidence of cerebral vasospasm (59% PRAV vs. 88% NP, P=0.0028).  However, the 
association was no longer significant after adjusting for WFNS score, race, elevated 
WBC, and clipping ( P=0.08).   This suggests that although there was a clinical trend 
towards decreased vasospasm in the PRAV group, any benefit from pravastatin therapy 
was not profound enough to remain statistically significant after other factors were taken 
into account.   Nevertheless, to address potential biases that may have arisen as a result of 
our exclusion criteria and the lack of consistent aneurysm treatment in all patients, we 
repeated the analysis both with the inclusion of clipping surgery and then without 
clipping surgery.   The results did change with this approach; pravastatin was associated 
with a statistically significant decrease in the incidence of vasospasm if clipping was not 
included.  It is possible that this finding was attributed to a skewed distribution of 
vasospasm in patients who received clipping surgery, which made up a majority of our 
study population and accounted for almost all the NP patients. We believe that the odds 
of vasospasm were affected by the type of surgical aneurysm treatment received by our 
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patients, raising the possibility that aneurysm treatment with endovascular coiling may 
benefit aSAH patients. 
It is important to note that there was a 29% decrease in the overall incidence of 
vasospasm in the PRAV group (88% to 59%) and in the vasospasm patients; the use of 
pravastatin was associated with a 27% decrease in the incidence of symptomatic 
vasospasm (97% to 70%).  Although, these differences were not statistically significant, 
they are clinically important and support further study of statins in aSAH patients.    
This study offers an important observation that elevated WBC may be associated 
with vasospasm after aSAH.  Logistic regression for vasospasm showed that elevated 
WBC was a statistically significant factor associated with the development vasospasm. 
Therefore, when the WBC count is elevated in aSAH patient, an unfavorable outcome is 
more likely to occur.  Some previous studies and multivariate analyses confirm these 
findings, which may or may not be related to the aSAH alone. (39, 41, 42, 46, 121) It is 
possible that some of the elevated WBC counts were related to infection rather than true 
vasospasm, suggesting that the neuroprotective and pleiotropic effects of pravastatin may 
not be observed in aSAH patients with infections or inflammatory processes.     
Even though it has been suggested that WFNS, tobacco, cocaine, and alcohol use, 
and younger patients have a higher tendency to suffer vasospasm, in our study we did not 
find an association between vasospasm and any of these factors.  A relationship between 
the WFNS score at presentation and outcomes has been shown in the past. (74-77) 
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Interestingly, the WFNS grade was not significantly associated with development 
of vasospasm in our study.  Smaller study groups like ours may underestimate these 
factors and is insufficient to draw any conclusion.  Also, the fact that WFNS was not 
highly predictive of outcomes in the multivariate analysis suggests that secondary factors 
may play a relatively more important role in the causation of poor outcomes after aSAH 
other than the clinical grade at admission. 
The proportion of subjects experiencing symptomatic vasospasm (clinical 
vasospasm symptoms with or without associated radiological evidence of vasospasm) in 
our study was 68% (n=55). The high reliability of this symptomatic vasospasm definition 
reduced the likelihood of underestimating or overestimating the diagnosis of vasospasm 
in our study.  
Approximately 75% of our study patients experienced cerebral vasospasm.  In the 
NP group 88% experienced vasospasm and in the PRAV group 59% experienced 
vasospasm. Moreover, the proportion of symptomatic vasospasm patients was 
significantly higher in the PRAV group (97%) than NP group (70%).  However, in Tseng 
study, only 5% of the patients receiving pravastatin had experienced symptomatic 
vasospasm, which is clearly lower than what was seen in our pravastatin patients. 
Interestingly, we observed that asymptomatic cerebral vasospasm, although it was in a 
small number of patients, may be increased with pravastatin use which was similar to 
previous reports in the literature. (126)  
Only eight patients had experienced clinical vasospasm without radiological 
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evidence. In addition, nine patients had experienced GCS decline and radiological 
confirmation without triple H, which were also considered to have symptomatic 
vasospasm. Those patients were not on vasopressors as part of triple H therapy because 
their blood pressures were already at target range.  
We detected no statistically significant difference in the incidence of radiographic 
vasospasm (angiographic vasospasm, elevated TCD vasospasm) or clinical vasospasm 
between the treatment groups among vasospasm patients. However, pravastatin users 
demonstrated a lower proportion of vasospasm confirmed by angiogram and/ or TCD, 
and a lower proportion of GCS decline during the same observation period. The 
difference in elevated TCD values between the two groups may be a result of differences 
in their baseline TCD velocities.  
Although the study design was not powered to detect a reduction in incidence of 
severe vasospasm, mortality, length of hospital stay, or home discharge outcome, we 
evaluated the effect of pravastatin on these outcomes. 
For the incidence of severe vasospasm, after using logistic regression to adjust for 
variations in race, WFNS score; number of comorbidities, and the method of aneurysm 
treatment (clipping surgery), the results remained similar in univariate and multivariate 
analysis. A statistically insignificant reduction (8%) in the incidence of severe 
radiological vasospasm was seen in PRAV patients (from 30% in NP group to 22% in 
PRAV). Larger studies are needed to confirm this trend as decreasing the incidence of 
72 
 
 
 
severe vasospasm is important clinically as it could lead to severe complications like 
delayed cerebral ischemia, infarction and consequently disability.   
In regards to length of hospital stay, after using logistic regression to adjust for 
variations in race, WFNS score, number of comorbidities, tobacco use, and the method of 
aneurysm treatment (clipping surgery), the results remained similar. A trend was 
observed suggesting that PRAV patients had a shorter hospital length of stay. This trend 
did not, however, achieve statistical significance. Although we did not find statistically 
significance difference between the two treatment groups in the hospital length of stay or 
NSICU length of stay, there was a significant clinical trend in hospital length of stay and 
NSICU length of stay between the vasospasm groups. This trend towards a decreased 
median length of stay (median=12.1 days in PRAV vs. 16.8 days in NP, P=0.06), may 
infer that pravastatin therapy may be associated with some cost savings by reducing the 
intensity of inpatient requirements for managing cerebral vasospasm. Previous study 
showed that cost, resource utilization and expenditures are high for treating vasospasm 
after aSAH especially in the acute care setting.(136)  
Furthermore, multivariate regression analysis showed that patients with WFNS 
scores III-V (poorer clinical status on admission) had longer hospital LOS, and patients 
with 0 or 1 comorbidity had shorter hospital LOS as reflected by their association with in 
the multivariate analysis.  
In regard to mortality, fourteen patients died during hospitalization. There were 9 
deaths in the PRAV group and 5 in the NP group.  In 5 of the 9 deaths in PRAV group, 
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there was no evidence of vasospasm. These five patients had continuing poor 
neurological function without evidence for vasospasm and died after withdrawal of care. 
Although we did not have a large enough sample size to determine differences in 
mortality, we built a logistic regression model to assess the mortality between the groups. 
We adjusted for variations in race, WFNS scores, tobacco use, number of comorbidities, 
and the method of aneurysm treatment (clipping surgery); the results remained similar in 
univariate and multivariate analysis. There was no significant difference in mortality 
between the groups (p =0.46). Our mortality result confirms the findings of Parra et al 
and Chou et al studies.  However, this finding contradicts the results of a prospective 
study conducted by Tseng et al. 
Sixty seven patients survived their hospitalization for aSAH.  At discharge, most 
PRAV patients achieved a favorable discharge disposition outcome, and there was 
statistically significant difference between the study groups.  Pravastatin was associated 
with a 58% increase in the home discharge disposition for the survivors. After using 
logistic regression to adjust for variations in race, WFNS scores, number of 
comorbidities, and the method of aneurysm treatment (clipping surgery), the results 
remained similar.  In our study, pravastatin therapy was associated with better discharge 
disposition in both the univariate analyses and the multivariate analysis, which raises the 
possibility that immediate treatment with pravastatin after aSAH may benefit those who 
survive aSAH as there was tendency toward reduced complication in the pravastatin 
group.  
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In addition, multivariate analysis identified that having 0 or 1 comorbidity 
increased the chance of being discharged to home as compared to those having more than 
1 comorbidity. Also, the analysis identified WFNS III-V as a variable decreases the home 
discharge. This may infer that having more than 1 comorbidity and WFNS III-V at 
admission may increase the disability at discharge.  
Interestingly, when the multivariate analysis was restricted to survivors among 
vasospasm patients, the effect of pravastatin on home discharge disposition slightly 
decreased.  However, multivariate analysis highlighted that pravastatin therapy is a 
predictor of improved outcome at discharge, despite the fact that more patients in the 
pravastatin group were more likely to have more than 1 comorbidity and aneurysm repair 
delayed after 72 hours, which could contribute to an unfavorable outcome.  
It is important to note that in the multivariate analysis for secondary outcomes, 
none of the variables that we adjusted for were significantly associated with mortality or 
the incidence of radiological severe vasospasm.  Importantly, we found that even with 
inclusion of these variables in the multivariable analyses (to correct for and eliminate 
their potential bias), this did not alter the findings (significance level) in regard to the 
association of pravastatin to the all secondary outcomes.  
In summary, pravastatin was associated with more favorable outcomes in aSAH 
patients. Generally, the observed beneficial effects (decreased trend in vasospasm and 
length of stay, and significantly associated with better discharge disposition) may suggest 
that the pleiotropic effects of pravastatin in aSAH patients has beneficial effects beyond 
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or in addition to treating vasospasm.  
These findings support the data from previous studies of pravastatin that suggest 
an association with favorable outcome in aSAH patients. (120-127) Our findings are 
more consistent with the findings of Parra et al and McGirt et al, demonstrating a 
reduction in the incidence of vasospasm with statin use. 
Although our study was in a small number of patients, it included  a slightly larger 
population than the previously published pravastatin Phase II randomized, controlled trial 
in aSAH patients, and was adequate for statistical analysis of our primary outcome based 
on our assumption that there would be a difference of 34%., (135)  However, the 
statistical analysis with this small number of patients has a large chance of a type II error, 
in which a significant difference is lost between the PRAV and NP groups.  A properly 
powered study, designed to detect a 29% difference between the vasospasm incidence of 
88% and 59% found in our study, should include more than 42 patients in each group. 
Our sample size calculation was based upon a 34% difference in vasospasm in incidence 
of statin use, which was not observed in our study.  
The demographic and clinical characteristics of our patients were similar to those 
of aSAH patients reported in earlier studies.  To our knowledge, there were no changes in 
our practice over time (Jan 2000- June 2008) that could have influenced the results. The 
study patients were all admitted to neuroscience care ICU and received the same 
treatments for aSAH (surgery, nimodipine, and triple H if needed) except for giving 
pravastatin, which was started in 2005. Statin users represented only 48% of our aSAH 
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patient sample. The most distinguished difference between groups was the type of 
aneurysm treatment. After reviewing all 596 aSAH patients and applying the inclusion 
and exclusion criteria for our study, significantly more PRAV patients were managed 
with aneurysm coiling than NP patients in our study. This may reflect an increase use of 
endovascular coiling treatment over time in our institution or selection bias. This change 
in practice may have biased the results against pravastatin use and made direct 
comparisons unclear and difficult. Furthermore, the quality of care of the patient may 
have changed although the treatment strategy did not change during the different time 
periods. Additionally, it is possible that the quality of imagining techniques used were 
different in the two periods which may have influenced the radiological diagnosis of 
vasospasm. 
The different results in the incidence of vasospasm seen in our study as compared 
to other studies may have been due to a significant difference between the two treatment 
groups in the following covariates: elevated Troponin-1, clipping surgery, number of 
comorbidities, and time to surgery. It is possible that these baseline differences may have 
masked the favorable effects of pravastatin and increased the incidence of vasospasm.  
The most significant distinction between the treatments groups was that almost all 
the NP group underwent to aneurysm clipping rather than coiling (the ratio of clipped 
patients to non-clipped patients was 2:1 in the NP: PRAV groups); therefore, it was 
important to adjust for surgical intervention type in our multivariate logistic regression, 
and also test the relation of clipping and vasospasm. In a univariate analysis, we found 
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that clipping was significantly associated with an increased the incidence of vasospasm, 
which we believe impacted our results. Therefore, the true effects of pravastatin cannot 
be determined and may not be fully understood since the type of surgical intervention 
was imbalanced.  If we could remove the surgical clipping effects from the multivariate 
analysis, pravastatin was associated with a decreased the incidence of vasospasm.  In our 
analysis, the risk of vasospasm is likely due to an imbalance (bias) in patients’ selection 
in regard to the aneurysm treatment method in the two study periods. Additionally, it is 
possible that the group of patients treated with clipping had a worse medical condition as 
noted by the increased proportion of patients with more than 1 comorbidity.  The 
reduction in the volume of subarachnoid clot at the time of aneurysm treatment may also 
play a role in this difference between treatment groups.  However, the exact mechanism 
of the relationship between aneurysm treatment methods and vasospasm in our study 
population was not studied.  
The choice to clip or coil is generally made by neurosurgeons. This decision may 
be based on the volume of hemorrhage; degree of neurological impairment; aneurysm 
location; dome, neck, and size characteristics; availability of practitioner; or any 
combination of these factors. Optimal management of aneurysms remains a controversial 
topic.  Several papers have been published in which investigators suggest an effect of 
either surgical or endovascular treatments on the development of vasospasm. (86-88) 
Some retrospective, nonrandomized studies found a higher incidence of vasospasm in the 
endovascular treatment group. (86, 88) However, in some of these studies, there was a 
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tendency to use endovascular techniques to treat patients with a worse clinical condition 
and worse degrees of aSAH.  Recently, a number of investigators have reported excellent 
outcomes using endovascular techniques and lower risks and complications associated 
clipping surgery.  To date, only one randomized study (ISAT) has been conducted in 
which authors compared the outcomes of open surgery and endovascular techniques in 
aSAH (The ISAT trial, 2002).  In this study, endovascular treatment was associated with 
a shorter LOS and a higher rate of being discharged to home.   However, these data 
should be further investigated. 
When we restricted the analysis only to patients who were clipped, there was still 
no statistical significant difference in the incidence of cerebral vasospasm across the two 
treatment groups.  However, the sample size was too small to compare only clipped 
patients to non-clipped patients in regards to cerebral vasospasm or other outcomes.  It is 
very important to note that we did see a significant improvement in the incidence of 
vasospasm with pravastatin when we removed clipping as a covariate from the 
multivariate logistic regression analysis; removing the other covariates in the multivariate 
analyses did not change the statistical significance. These results confirm that clipping 
negatively impacts outcomes after aSAH. (137) Among all the previous studies, Kramer 
et al. and our study are the only studies that adjusted for the type of surgical intervention.  
It would be possible that if the other studies had adjusted for the effect of clipping, their 
results may have changed. (Table 34)  
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Triple H therapy was used for all patients with clinical vasospasm.  In this study, 
we found that pravastatin significantly reduced the need for use of triple H therapy in the 
PRAV group.  This is consistent with the assumption that statins improve the endothelial 
function and reduced the inflammatory process.  We measured the time to start triple H 
therapy as surrogates for vasospasm onset, and number of days on triple H therapy as 
surrogates for vasospasm duration, and once again detected no difference between the 
treatment groups. Use of Triple H therapy was first reported an average of 4 days after 
admission for the aSAH, with the majority of cases being treated between Days 3 and 4.    
However, the median days to triple H therapy was significantly longer in the PRAV 
group than NP group (median=3 [Range 1-15] in NP vs. median=4 [Range 2-8] in 
PRAV, P=0.0438).  In those whom vasospasm still occurred in the pravastatin group, 
delay in the time to start triple H therapy may suggest a protective effect as seen in 
previous studies. (115-119)  The median duration therapy was similar in both groups 
(approximately 6 days, p=0.121).   
 The exact explanation for why some of our findings differed from other 
researches remains uncertain.  However, differences in study methodology used such as 
different criteria to diagnose and manage vasospasm, failure to control for confounding 
variables (e.g. method of aneurysm treatment), differences in sample sizes, and different 
study designs probably played a role. (Table 32-34)  
Another possible explanation for our findings regarding the incidence of 
vasospasm is the difference in the treatment regimen. To help avoid more confounders, 
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we did not include prior statin users. Two of the three prospective studies (Chou et al. and 
Tseng et al.) excluded the subjects who are on a statin prior to admission. While Lynch et 
al. allowed 3 patients who were on a statin to be in the analysis. Among the retrospective 
studies done to date, our study and Kramer et al. study are the only studies that excluded 
any previous statin users.  In those studies with previous statin users, inclusion of prior 
users of statin may have contributed to favorable outcome in the statin group compared to 
placebo or control. We excluded patients with prior statin use to eliminate an additional 
confounding variable that may have impacted outcomes.  
Additionally, there were differences among the studies in the enrollment criteria. 
Cerebral vasospasm generally begins within 4-7 days after aSAH.  Statin treatment was 
started within 96 hours of aSAH in most of the previous studies. To avoid missing the 
time window for beneficial effects, we restricted our investigation to patients who were 
seen within 48 hours after aSAH and were initiated on 40mg therapy within 72 hours 
aSAH. These inclusion criteria were in line with previous studies and may have 
contributed to some of the beneficial effects observed in our study. (Table 28) 
In addressing the potential biases that may have come up as a consequence of our 
inclusion and exclusion criteria, our population was selected based on the time to 
admission (within 48hours after aSAH,).  This aspect affected the number of cases in our 
population. We only include patients that received treatment before the high-risk period 
of vasospasm in order to balance the population, which does not allow studying outcomes 
that are similar to those found in the general population of patients with aSAH.  Also, this 
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could bias the selection of cases toward patients with less severe conditions, and may 
have reduced the impact of time on the development of the vasospasm and poor outcome.  
Moreover, there were differences among the studies in the length of statin therapy 
evaluation. The optimal duration of statin therapy has not been determined.  In our study, 
the pravastatin therapy was continued until the patient was discharge from the hospital or 
completed 21 days. This duration corresponds with the risk of having vasospasm up to 
the three weeks after aSAH. Only 36% of our patients completed three weeks of 
pravastatin therapy, with a mean of duration of pravastatin use of 13.80 days (SD ± 
6.338). There was no significant difference in the incidence of vasospasm between the 
two stratified durations of pravastatin use. This is consistent with studies conducted by 
Tseng et al. and Lynch et al. where therapy was continued for 14 days.  
One of the possible explanations for our findings regarding the incidence of 
vasospasm is the difference in vasospasm definitions among all studies. The literature has 
used a variety of definitions of vasospasm using terms including clinical vasospasm, 
TCD vasospasm, and angiographic vasospasm. Each definition has its own strengths and 
limitations. The clinical diagnosis of vasospasm is a subjective diagnosis, and the 
relationship between angiographic vasospasm and clinical symptoms can be inconsistent. 
It is possible that with strong clinical indications of vasospasm, that a small reduction in 
the diameter of the arteries would cause a diagnosis of vasospasm in regular clinical 
circumstances.  The diagnosis of clinical vasospasm was based on the information 
collected in the charts. 
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In consideration of the limitations of a retrospective study, we made specific and 
clear definition of vasospasm. We used the combined definition based on literature that 
showed that the clinical factors significantly associated with vasospasm after aSAH with 
TCD velocities or angiography measures improve the accuracy of cerebral vasospasm 
diagnosis. Several studies have identified that the combining of radiological information 
with additional clinical information could support the diagnosis of vasospasm. (50-66) 
From the clinical point of view, the results of our study are useful as evidence of the 
relationship between clinical, TCD and angiographic vasospasm and the nature of that 
relationship.  
In our study, we defined vasospasm by clinical, TCD velocity, or angiographic 
criteria. Previous studies that assessed statins for the prevention of vasospasm have used 
different measurements, and reported different outcomes such as incidence of 
radiological vasospasm clinical and TCD velocity, a reduction in rescue therapy, 
improved functional outcomes, enhanced autoregulation indices and improvement in the 
duration of impaired cerebral autoregulation. (Table 32) In addition, the previous studies 
have used different definitions of radiological and clinical cerebral vasospasm. (Table 33) 
One example of the differences in vasospasm definition is the TCD velocity readings 
interpretation. Tseng et al used mean MCA flow velocity of >120 cm/s as definition of 
vasospasm, whereas Lynch et al. defined TCD vasospasm as mean MCA flow velocity of 
>160 cm/s, while Chou et al. and McGirt et al, considered TCD velocity>200 as 
vasospasm.  
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Radiological vasospasm was identified in our study from computed tomographic 
angiography or TCD velocity reports. Both Phase II trials only used TCDs to indicate 
vasospasm. Using TCD velocity for diagnosis of vasospasm presents difficulty in 
measurement and interpretation; however, statistically significant associations between 
TCD velocities and angiography have been reported.(59, 138) Therefore, the combination 
of radiological (TCD velocity and angiography) and clinical diagnosis is a powerful 
predictor of vasospasm. . 
Incidence of vasospasm was also relatively higher than that previously reported in 
other statin studies.  This is possibly explained by the definitions of vasospasm in our 
main analysis.  These incidences are very close to what has been published for vasospasm 
(50–70%).(12, 13)  Additionally, the observed reduction in vasospasm may have been to 
some extent explained by an uncommonly high rate of vasospasm among NP patients 
(88%).   
In regard to TCD vasospasm, it is possible that some of the elevated velocities 
recorded were related to hyperemia rather than vasospasm. Lindegaard ratios, which 
would have allowed for such differentiation, were not recorded. TCD monitoring is an 
examination that is operator dependent and requires the establishment of critical 
thresholds and quality control at each institution.  
The results of our study showed that cerebral vasospasm had a great impact on 
aSAH patient outcomes. We found that the median hospital length of stay in the 
vasospasm group was significantly higher than the no-vasospasm group (median=11.1 
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[Range 3-56.4] in no-vasospasm group versus median=16.5 [range 3-129] in vasospasm 
group). Similarly we found that the median NSICU-LOS was significantly longer in the 
vasospasm group (median=5.7 [Range 2.2-27] in no-vasospasm group versus 
median=13.2 [range 3-49.4] in vasospasm group, p=0.0018).  In addition, the proportion 
of patients who were discharged to a facility other than home was significantly higher in 
the vasospasm group (p=0.002).  All the patients who did not experience vasospasm were 
discharged to home.  Although, there was no statistical significant difference in 
proportion of mortality between the two vasospasm groups (p=0.358), approximately 
64% (n=9) of expired patients had experienced cerebral vasospasm. These observations 
indicate that vasospasm is an important factor in determining the outcomes of aSAH 
patients.  However, it is possible that some other comorbidities, medical therapy (e.g. 
triple H therapy), or medical procedures during hospitalization may have led to other 
complications contributed to these poor outcomes.   
 
Strengths and Limitations:  
Strengths of our study include that 73% of vasospasm patients were diagnosed 
radiologically versus clinically only.  In addition, there was consistency in our diagnostic 
methods and management protocol for vasospasm in aSAH during the study period. 
Another strength of our study is that we are the first study to investigate the effects of 
pravastatin throughout the admission period or a maximum of 21 days. We also adjusted 
for potential confounding factors which appear to impact the effects of pravastatin on the 
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incidence of vasospasm.  A limitation of our study is that it was a retrospective design; 
therefore, cause and effects cannot be determined. Additionally, we had limited 
knowledge about exposure to nonprescription drugs such as cocaine, which could 
increase the risk for vasospasm.  It is also possible that ICD-9 coding errors resulted in 
our omission of aSAH patients or the comorbidity data. Furthermore, the study only 
evaluated pravastatin use and may not be able to be extrapolated to other statins.  Another 
limitation of this study is that the optimal dose of pravastatin in the clinical setting is not 
yet determined and this may have impacted our results. 
The observations in a single institute, the relatively small sample size, and the 
overwhelming effects of surgical clipping on aSAH outcome affect the generalizability of 
our study.  Although factors commonly associated with cerebral vasospasm were 
recorded and adjusted for in our analyses, the retrospective nature of this study prevents 
the elimination of all possible confounding factors which could affect this analysis.  
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Table 32: General Characteristics of Studies Evaluating Statin Effects in aSAH 
Patients 
Study  Design 
Intervention 
Sample Size 
Primary Objectives & Outcomes 
Length of Statin Therapy Evaluation 
Tseng et al. 
2005 
DBRCT 
Pravastatin 40mg 
(n=40) 
Placebo, n=40 
Incidence, duration, and severity of cerebral vasospasm, and duration of impaired 
autoregulation. The frequency and intensity for rescue therapy, length of inpatient stay, 
Outcome at Discharge and long-term outcome at 6 months 
Evaluated for 14 days 
Lynch et al. 
2005 
DBRCT n=39  
Simvastatin 80mg 
(n=19) 
Placebo= 20 
Incidence of vasospasm. Evaluated for 14 days 
Chou et al. 
2008 
DBRCT 
Simvastatin 80mg 
(n=19) 
Placebo= 20 
Death and incidence of drug morbidity. Secondary outcomes included incidence of 
transcranial Doppler (TCD), angiographic or clinical vasospasm, vasospasm-related infarcts, 
clinical outcomes at discharge, and cardiac and infectious morbidities. Length of evaluation 
of statin therapy was not reported 
Parra et al. 
2004 
1:2 matched 
Retrospective n=60 
Any statin (n=20) 
Functional outcome at 14. Secondary outcomes were 14-day mortality, Modified Rankin 
Scale score, DCI, cerebral infarctions of any type, and TCD highest mean velocity elevation. 
Evaluated for 14 days 
Singhal et al. 
2005 
Retrospective-
cohort 
n=514  
Any statin(n=36) 
Risks for vasospasm, symptomatic vasospasm, and poor clinical outcomes. were evaluated 
for vasospasm between days 4 and 14. 
McGirt et al. 
2006 
Retrospective-
cohort115  
statin (n=15) 
to assess factors predictive of symptomatic vasospasm  
The odds of subsequent symptomatic vasospasm onset. Evaluated through hospital stay. 
Kramer et al. 
2008 
Retrospective-
cohort n=150  
Simvastatin 80m 
(n=71) 
The occurrence of vasospasm, delayed infarction, or poor outcome (death, vegetative state, or 
severe disability). Evaluated for 14 days 
Our study 
2009 
Retrospective-
cohort n=81      
Pravastatin 40mg 
n=39 
Incidence of vasospasm, incidence of severe vasospasm, mortality, length of stay, clinical 
outcomes at discharge. Evaluated Until discharge from hospital, or a maximum of 21 days. 
DBRCT=Double Blind Randomized Clinical Trial 
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Table 33: Cerebral Vasospasm Definitions in Studies Evaluating Statin Effects in 
aSAH Patients 
 
. Cerebral 
Vasospasm 
Criteria 
Clinical 
Definition 
 
Radiological Definition 
 
Tseng et al. Radiological 
only 
NR  >120 cm/s with Lindegaard ratio (LR) > 3. 
Lynch et al. Radiological 
and 
biochemical 
markers  
Clinical impression of a delayed ischemic 
neurological deficit  
TCD MCA >160 m/sec by TCD or 
Angiography 
Chou et al. Radiological 
only 
NR Angiographic vasospasm was defined as focal or 
reduction of cerebral arterial caliber on conventional 
cerebral angiogram. TCD MCA >200 cm/s and a 
Lindegaard ratio of >3. 
Parra et al. Radiological 
only 
NR TCD-HMV is ≥120 cm/s or angiograph, TCD-HMV 
change of ≥50 cm/s 
Singhal et al. 
 
Radiologic and 
clinical 
Symptomatic vasospasm was defined as a 
focal neurologic deficit in the territory of the 
basal or cortical arteries  
or a decline in level of consciousness; the 
neurologic worsening had to be associated 
with cerebral vasospasm  
TCDs for the basilar artery are ≥120. TCD for other 
cerebral arteries ≥200 cm/second values, Lindegaard’s 
ratio was used. 
McGirst et al. 
 
Radiologic and 
clinical 
Either angiographic vasospasm or the TCD ≥ 
200 cm/second and neurological 
improvement was  
observed during triple-H therapy. 
Cerebral vasospasm was diagnosed in patients with 
DINDs if they improved with triple-H therapy and 
their TCD ultrasonography flow velocities were >200 
cm/second, or angiographic VSP despite partial or no 
response to triple-H therapy. 
Kramer et al. Reported as 
Radiological 
or clinical 
 Neurological deterioration, radiographic 
vasospasm, physician decision to treat. 
Angiographic >30% narrowing. 
Our study 
 
Radiologic 
and/or clinical 
Received 2 of the 3 aspects of triple-H 
therapy, onset of neurological deficit or 
change of neurological deficit severity, or 
drop in Glasgow Coma Scale by ≥ 2 points  
TCD double of the baseline value or are > 120 cm/sec; 
or angiographic vasospasm 
 
 
NR= Not reported 
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Table 34: Method Characteristics of all the Studies Evaluating Statin Effects in SAH 
Outcomes to Date 
 
. Included 
Previous 
Statin 
Users 
Enrollment 
Time Criteria  
Clipped 
 
Coiled 
 
No surgical 
intervention 
Statistical 
Adjustment 
for Clipping  
Tseng et al. No ≤ 72 hrs. Placebo: 
62.5% 
Prav: 67.5% 
P= 0.686 
Placebo: 15% 
Prav: 17.5% 
P= 0.686 
Placebo: 
22.5% 
Prav: 15% 
P= 0.686 
No 
Lynch et al Yes,  
n=3 
NR Placebo: 
40% 
Sim.: 47% 
Placebo: 60% 
 Sim.: 53% 
0  No 
Chou et al. No ≤ 96 hours  Placebo:  
(80%)   
Sim.:  
(89%) 
NR NR No 
Parra et al. Yes, 
n=25  
≤ 14 days Stated equal 
number in 
each groups 
Stated equal 
number in 
each groups 
0 No 
Singhal et al. 
 
Yes, 
n=19  
≤ 14 days Clipped 
80% 
Detail NR 
 
Coiled 19% 
Clipped and 
coiled 1% 
Detail NR 
NR No  
McGirt et al. Yes NR NR NR NR No 
Kramer et al. Yes,  
n=5  
≤ 72 hours  Control 
:(63%)  
Sim.  (42%)  
P = <0.01 
Control:(33%) 
Sim.:  (55%) 
P = <0.01 
Five patients  Yes 
Our study No ≤ 48 hrs Control: 
98% 
Prav: 51% 
p <0.0001 
Control: 2% 
Prav: 26% 
Control:0% 
Prav:25% 
Yes 
Prav= pravastatin, Sim= simvastatin, NR= not reported 
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Table 35: Results of all Studies Evaluating Statin Effects in SAH Outcomes to Date 
 
Study Incidence of 
Any VSP 
or Radiological 
VSP   
Incidence of 
Symptomatic 
VSP 
Incidence of 
Severity or Severe 
VSP 
LOS Mortality Length of Triple H 
Therapy 
Outcome at 
discharge 
Tseng et al. 
 
Placebo: 62.5 
Prav: 42.5%  
P= 0.006 
NR Placebo 30%  
Prav: 17.5% 
P= 0.044 
NSDF Placebo:20%   
Prav: 5% 
P= 0.037 
NR  NSDF 
Lynch et al. 
 
Placebo=60%  
Sim=26%  
P= 0.03 
NR NR NR NR NR NR 
Chou et al. Radiological 
Placebo: (50%)  
Sim:  (68%)  
P=0.24 
NR NR Placebo: 18±9 
Sim: 20±12  
P= 0.74 
 
Placeb: 15%   
Sim: 0%  
P= 0.23 
 
Placebo: Median=2   
Sim. Median=2 
P= 0.86 
To home      
Plac: 35% 
Sim: 42%  
P= 0.65 
Parra et al. Control: 51%  
Statin: 18%   
P=0.03 
 
NR NR NR Control:13% 
Statin: 20%   
P= 0.46 
NR Used MRS, BI, 
and  
Lawton-PSMS 
scores. 
Singhal et al. 
 
Univaraite User: 
OR  2.25 CI 
(0.97–5.83) p= 
0.05 
Univaraite Statin 
discontinued: OR: 
2.35  
CI (0.74–9.88)  
P= 0.15 
All vasospasm 319 
(62%) 
Univaraite 
User: 
OR 1.62  CI 
(0.74–3.41) 
0.18 
univaraite 
Statin 
discontinued: 
OR OR  2.28  
CI (0.80–6.34)  
P=0.12 
 
NR NR Statin group 
 OR: 0.44  
CI (0.14–1.40)  
P= 0.17 
All death: 
12% 
 
 
NR Used MRS 
McGirt et al. 
 
Used sym. as 
definition for VSP 
Control: 48% 
Statin: 6.6% 
P= 0.002 
NR NR NR NR NR 
Kramer et al. 
 
Radiological: 
Control: 33 (42%)  
Sim: 29 (41%)  
P= 0.91 
(Reported as radio 
and clinical VSP) 
 
Plac: 20 (25%)  
Sim: 23 (32%)  
P= 0.34 
Control: 42% 
Sim: 41% 
Simvastatin 
did not decrease 
radiographic 
moderate to severe 
VSP  
NR  NR Poor outcome 
was defined as a 
GOS score of 1-3 
(death, 
vegetative state, 
or severe 
disability) 
Our study 
 
Control: 88% 
Prav: 59%   
Adjusted P=0.25 
Control: 86% 
Prav: 42% 
P=0.002 
Control: 26% 
Prav: 13% 
P=0.463 
Control: 
median=16.8 
Prav: 
median=12.1 
P=0.061 
Control: 12% 
Prav: 23% 
P=0.184 
Control: Median=6.5 days 
Prav: Medians=6 days 
P= 0.121 
Control: 40% 
Prav: 74% 
P<0.0001 
VSP= vasospasm, Modified Rankin Scale (MRS), Barthel Index (BI), and Modified Lawton Physical Self Maintenance Scale (Lawton-PSMS), Prav= 
pravastatin, Simv= simvastatin, NR= not reported 
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CHAPTER 5 CONCLUSIONS 
 
 We concluded that there was a trend towards a decrease in the incidence of 
vasospasm in the aSAH receiving pravastatin, but this trend did not achieve statistical 
significance after adjusting for potential confounders. Pravastatin therapy was not 
associated with a decrease in the incidence of radiological severe vasospasm or a 
reduction in mortality in aSAH patients. Although, the effect of pravastatin was not to the 
same degree and extent of positive effects as shown by earlier studies, pravastatin 
appeared to provide some other clinical benefit. We did demonstrate a trend toward a 
decrease in hospital LOS and a significant favorable discharge disposition in patients who 
received pravastatin therapy, so one possible conclusion is that they have other beneficial 
effects in addition to treating vasospasm. We believe the pleiotropic effects of pravastatin 
may be responsible for some of the observed favorable (protective) benefits after aSAH 
as seen in the pravastatin group in this study.   
Also, favorable outcomes were more likely in patients whose aneurysms are 
coiled rather than clipped in our study.  The clinical value of statin therapy initiated after 
aSAH remains unclear because surgical clipping was done for 98% of NP treated patients 
and 51% of PRAV patients and this may have impacted our results.   However, our 
results showed that among the PRAV group, the proportion of patients who experienced 
vasospasm was significantly higher in the clipped group as compared to non-clipped 
group, which suggest that there may be an effect of pravastatin on vasospasm if patient 
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were not clipped. Despite the limitations of this investigation, the results of this study 
support the use of statins in aSAH and the main findings from this analysis will have 
important implications for the treatment of aSAH.  Further investigation of statin therapy 
for the prevention and treatment of cerebral vasospasm is needed.  
 
Future Direction 
The results of this analysis are encouraging and interesting.  More information is 
required before any therapeutic recommendation can be fully supported. Cerebral 
vasospasm is a not fully understood complication and is associated with many different 
factors. Studying the pathophysiology of vasospasm can provide key pathways for future 
research. Although we found that pravastatin treatment was not statistically associated 
incidence of vasospasm, prospective multicenter controlled studies are needed to validate 
our findings, to better evaluate the potential benefits of statins in the treatment of aSAH, 
and to determine optimal dosage, choice of statins, and duration of treatment.  Although 
the association of elevated WBC with vasospasm confirms findings of previous studies, 
(46) further research into the duration of therapy and conditions that may be associated 
with vasospasm should also be considered.  
Once the advantages of clipping and non-clipping surgery in aSAH patients are 
established, the possible benefit of starting a statin after aSAH should be considered.  It 
will be very interesting to see the long-term protective effect of statins after following-up 
of these patients and assessing their outcomes at 1 year after the aSAH. 
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